Methods for treating Huntington's disease
By using specifically substituted monocyclic heteroaryl compounds, the lack of effective treatments for Huntington's disease has been addressed, providing potential avenues for treatment or improvement.
Patent Information
- Application Number
- CN202110932557.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2015-12-10
- Filing Date
- 2016-12-11
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2036-12-11
AI Technical Summary
Currently, there are no effective small molecule compounds to treat Huntington's disease (HD), and existing treatments are insufficient to meet clinical needs.
Using a compound of formula (I) or in its form, including a specially substituted monocyclic heteroaryl compound, to treat or improve Huntington's disease by administering an effective amount of the compound or a combination thereof to a subject, alone or in combination with other agents.
This provides potential treatments or ways to improve Huntington's disease, which may have a positive effect on symptoms by using specific substituted monocyclic heteroaryl compounds.
Smart Images

Figure CN113717154B_ABST
Abstract
Description
[0001] This application is a divisional application of an invention patent application with an application date of December 11, 2016, application number 201680081666.1, and invention name “Method for treating Huntington's disease”. Technical Field
[0002] The present invention relates to compounds, forms thereof, and pharmaceutical compositions thereof, as well as methods for treating or improving Huntington's disease using these compounds, forms thereof, or compositions thereof. Specifically, the present invention relates to substituted monocyclic heteroaryl compounds, forms thereof, and pharmaceutical compositions thereof, as well as methods for treating or improving Huntington's disease using these compounds, forms thereof, or compositions thereof. Background Art
[0003] Huntington's disease (HD) is a progressive, autosomal dominant neurodegenerative disease of the brain with symptoms characterized by involuntary movements, cognitive impairment and mental decline. Death usually occurs 13 to 15 years after the onset of symptoms (usually caused by pneumonia or coronary artery disease). In a population of Western European descent, the prevalence of HD is 3 to 7 people per 100,000 people. In North America, it is estimated that 30,000 people suffer from HD, while another 200,000 people have the risk of inheriting the disease from sick parents. The disease is caused by the amplification of the uninterrupted trinucleotide CAG repeats in the "mutated" Huntington (Htt) gene, resulting in the production of HTT (Htt protein) with an amplified polyglutamine (polyQ) sequence (stretch) (also referred to as a "CAG repeat" sequence). There is currently no small molecule therapy for the root cause of the disease, leaving a high unmet demand for drugs that can be used to treat or improve HD. Therefore, it is still necessary to determine and provide small molecule compounds for treating or improving HD.
[0004] All other documents cited herein are hereby incorporated by reference into this application as if fully set forth herein. Summary of the invention
[0005] The present invention relates to a method for treating or ameliorating HD in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of formula (I), or a form thereof and a composition thereof:
[0006]
[0007] wherein W, X, A and B are as defined herein.
[0008] In particular, the present invention relates to the use of a compound of formula (I) or a form thereof or a composition thereof in a method for treating or ameliorating HD in a subject in need thereof, said use comprising administering to the subject an effective amount of the compound or a form thereof or a composition thereof.
[0009] The present invention also relates to the use of a compound of formula (I) or a form thereof in combination with an agent having additive or synergistic activity, thereby providing a combination product for the treatment of HD. DETAILED DESCRIPTION
[0010] The present invention relates to a method or use of a compound for treating or ameliorating HD in a subject in need thereof, the method or use comprising administering to the subject an effective amount of a compound of formula (I), or a form thereof:
[0011]
[0012] in
[0013] W is CH=CH or S;
[0014] X is CH2, CH(C 1-4 alkyl), C(C 1-4 alkyl)2, CH=CH, O, NR5, or a bond;
[0015] A is aryl, heteroaryl, heterocyclic, or C 9-10 Cycloalkyl,
[0016] wherein aryl is selected from phenyl and naphthyl, each optionally substituted by 1, 2, 3, or 4 substituents, each substituent selected from R1,
[0017] Wherein the heteroaryl group is a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure group, wherein, where the structural stability permits, one or more carbon atom ring members are replaced by one or more heteroatoms (e.g., O, S or N atoms), and each aromatic carbon atom ring structure group is optionally substituted by 1, 2, 3, 4, or 5 substituents, each of which is selected from R1,
[0018] wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O or S, each ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2, and
[0019] Among them C 9-10 Cycloalkyl is a saturated or partially unsaturated bicyclic ring system, each of which is optionally substituted with 1, 2, 3, 4, or 5 substituents, each of which is selected from R2;
[0020] B is a heterocyclic group,
[0021] wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O or S, each ring system optionally substituted with 1, 2, 3, 4, or 5 substituents, each substituent selected from R4;
[0022] R1 is halogen, hydroxyl, cyano, C 1-4 Alkyl, halogenated C 1-4 Alkyl, amino, C 1-4 Alkyl-amino, (C 1-4 alkyl)2-amino, amino-C 1-4 Alkyl, C 1-4 Alkyl-amino-C 1-4 Alkyl, (C 1-4 alkyl)2-amino-C 1-4 Alkyl, amino-carbonyl, C 1-4 Alkyl-amino-carbonyl, (C 1-4 alkyl) 2-amino-carbonyl, C 1-4 Alkyl-amino-carbonyl-C 1-4 Alkyl, (C 1-4 alkyl)2-amino-carbonyl-C 1-4 Alkyl, C 1-4 Alkyl-carbonyl-amino, C 1-4 Alkyl-carbonyl-amino-C 1-4 Alkyl, Hydroxyl-C 1-4 Alkyl, C 1-4 Alkyl-carbonyl, C 1-4 Alkoxy, halo-C 1-4 Alkoxy, amino-C 1-4 Alkoxy, Hydroxyl-C 1-4 Alkoxy, C 1-4 Alkyl-C 1-4 Alkoxy, C 1-4 Alkyl-amino-C 1-4 Alkoxy, (C 1-4 alkyl)2-amino-C 1-4 Alkoxy, C 1-4 Alkyl-carbonyl-amino-C 1-4 Alkoxy, C 1-4 Alkoxy-C 1-4 Alkoxy, C 1-4 Alkoxy-carbonyl, C 1-4 Alkoxy-carbonyl-amino, C 1-4 Alkoxy-carbonyl-amino-C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkenyl-amino-carbonyl, C 3-7 Cycloalkyl, C 3-7 Cycloalkyl-C 1-4Alkoxy, C 3-7 Cycloalkenyl, heteroaryl, heteroaryl-C 1-4 Alkyl, Heteroaryl-C 1-4 Alkyl-amino, heteroaryl-C 1-4 Alkyl-amino-carbonyl, heteroaryl-C 1-4 Alkyl-carbonyl-amino, heteroaryl-C 1-4 Alkyl-amino-carbonyl-C 1-4 Alkyl, Heteroaryl-C 1-4 Alkyl-carbonyl-amino-C 1-4 Alkyl, heterocyclyl, heterocyclyl-C 1-4 Alkyl, heterocyclic-C 1-4 Alkoxy, phenyl, or phenyl-C 1-4 Alkoxy,
[0023] Wherein the heteroaryl group is a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure group, wherein one or more carbon atom ring members are replaced by one or more heteroatoms (e.g., O, S or N atoms) where the structural stability permits,
[0024] wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O and S, and
[0025] wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1 or 2 substituents, each substituent selected from R3;
[0026] R2 is halogen, hydroxy, cyano, oxo, hydroxy-imino, C 1-4 Alkyl, halo-C 1-4 Alkyl, amino, C 1-4 Alkyl-amino, (C 1-4 alkyl)2-amino, amino-C 1-4 Alkyl, C 1-4 Alkyl-amino-C 1-4 Alkyl, (C 1-4 alkyl)2-amino-C 1-4 Alkyl, amino-carbonyl, hydroxy-C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Alkoxy-carbonyl, C 2-4 Alkenyl, C 3-7 Cycloalkyl or heterocyclic-C 1-4 alkyl,
[0027] wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2 or 3 heteroatom ring members selected from N, O and S, and
[0028] wherein each instance of heterocyclyl is optionally substituted with 1 or 2 substituents, each substituent selected from R3;
[0029] R3 is halogen, hydroxy, nitro, oxo, hydroxy-imino, C 1-4 Alkyl, halo-C 1-4 Alkyl, amino, C 1-4 Alkyl-amino, (C 1-4 alkyl)2-amino, amino-C 1-4 Alkyl, C 1-4 Alkyl-amino-C1-4 alkyl, (C 1-4 alkyl)2-amino-C 1-4 Alkyl, amino-carbonyl, C 1-4 Alkyl-amino-carbonyl, (C 1-4 alkyl) 2-amino-carbonyl, C 1-4 Alkyl-amino-carbonyl-C 1-4 Alkyl, (C 1-4 alkyl)2-amino-carbonyl-C 1-4 -alkyl, C 1-4 Alkyl-carbonyl-amino, C 1-4 Alkyl-carbonyl-amino-C 1-4 Alkyl, Hydroxyl-C 1-4 Alkyl, C 1-4 Alkyl-carbonyl, C 1-4 Alkoxy, halo-C 1-4 Alkoxy, amino-C 1-4 Alkoxy, Hydroxyl-C 1-4 Alkoxy, C 1-4 Alkyl-C 1-4 Alkoxy, C 1-4 Alkyl-amino-C 1-4 Alkoxy, (C 1-4 Alkyl)2-amino- 1-4 Alkoxy, C 1-4 Alkyl-carbonyl-amino-C 1-4 Alkoxy, C 1-4 Alkoxy-C 1-4 Alkoxy, C 1-4 Alkoxy-carbonyl, C 1-4 Alkoxy-carbonyl-amino, C 1-4 Alkoxy-carbonyl-amino-C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkenyl-amino-carbonyl, C 3-7 Cycloalkyl, C 3-7 Cycloalkyl-C 1-4 Alkoxy, C 3-7 Cycloalkenyl, heteroaryl, heteroaryl-C 1-4 Alkyl, Heteroaryl-C1-4 Alkyl-amino, heteroaryl-C 1-4 Alkyl-amino-carbonyl, heteroaryl-C 1-4 Alkyl-carbonyl-amino, heteroaryl-C 1-4 Alkyl-amino-carbonyl-C 1-4 Alkyl, Heteroaryl-C 1-4 Alkyl-carbonyl-amino-C 1-4 Alkyl, heterocyclyl, heterocyclyl-C 1-4 Alkyl, phenyl, or phenyl-C 1-4 Alkoxy;
[0030] R4 is independently selected from halogen, C 1-4 Alkyl, Hydroxyl-C 1-4 Alkyl, amino, C 1-4 Alkyl-amino, (C 1-4 alkyl) 2-amino, or hydroxy-C 1-4 Alkyl-amino; and
[0031] R5 is hydrogen, C 1-4 Alkyl, or hydroxy-C 1-4 alkyl;
[0032] wherein the form of the compound is selected from the group consisting of: its prodrug form, salt form, hydrate form, solvate form, clathrate form, isotopologue form, racemate form, enantiomer form, diastereoisomer form, stereoisomer form, polymorph form and tautomer form.
[0033] Embodiments of the present invention also relate to methods or uses of compounds for treating or ameliorating HD in a subject in need thereof, the methods or uses comprising administering to the subject an effective amount of a compound of formula (I) or a form thereof, wherein the compound of formula (I) is selected from compounds of formula (Ia) and formula (Ib):
[0034]
[0035] in
[0036] X is CH2, CH(C 1-4 alkyl), C(C 1-4 alkyl)2, CH=CH, O, NR5, or a bond;
[0037] A is aryl, heteroaryl, heterocyclic, or C 9-10 Cycloalkyl,
[0038] wherein aryl is selected from phenyl and naphthyl, each optionally substituted by 1, 2, 3, or 4 substituents, each substituent selected from R1,
[0039] Wherein the heteroaryl group is a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure group, wherein, where the structural stability permits, one or more carbon atom ring members are replaced by one or more heteroatoms (e.g., O, S or N atoms), and each aromatic carbon atom ring structure group is optionally substituted by 1, 2, 3, 4, or 5 substituents, each of which is selected from R1,
[0040] wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O or S, each ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R2, and
[0041] Among them C 9-10 Cycloalkyl is a saturated or partially unsaturated bicyclic ring system, each bicyclic ring system is optionally substituted with 1, 2, 3, 4, or 5 substituents, each substituent is selected from R2;
[0042] B is a heterocyclic group,
[0043] wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O or S, each ring system optionally substituted with 1, 2, 3, 4, or 5 substituents, each substituent selected from R4;
[0044] R1 is halogen, hydroxyl, cyano, C 1-4 Alkyl, halogenated C 1-4 Alkyl, amino, C 1-4 Alkyl-amino, (C 1-4 alkyl)2-amino, amino-C 1-4 Alkyl, C 1-4 Alkyl-amino-C 1-4 Alkyl, (C 1-4 alkyl)2-amino-C 1-4 Alkyl, amino-carbonyl, C 1-4 Alkyl-amino-carbonyl, C 1-4 Alkyl-amino-carbonyl-C 1-4 Alkyl, C 1-4 Alkyl-carbonyl-amino, C 1-4 Alkyl-carbonyl-amino-C 1-4 Alkyl, Hydroxyl-C 1-4 Alkyl, C 1-4 Alkyl-carbonyl, C 1-4 Alkoxy, halo-C 1-4 Alkoxy, amino-C 1-4 Alkoxy, Hydroxyl-C 1-4 Alkoxy, C 1-4 Alkyl-C 1-4Alkoxy, C 1-4 Alkyl-amino-C 1-4 Alkoxy, (C 1-4 alkyl)2-amino-C 1-4 Alkoxy, C 1-4 Alkyl-carbonyl-amino-C 1-4 Alkoxy, C 1-4 Alkoxy-C 1-4 Alkoxy, C 1-4 Alkoxy-carbonyl, C 1-4 Alkoxy-carbonyl-amino, C 1-4 Alkoxy-carbonyl-amino-C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkenyl-amino-carbonyl, C 3-7 Cycloalkyl, C 3-7 Cycloalkyl-C 1-4 Alkoxy, C 3-7 Cycloalkenyl, heteroaryl, heteroaryl-C 1-4 Alkyl, Heteroaryl-C 1-4 Alkyl-amino, heteroaryl-C 1-4 Alkyl-amino-carbonyl, heteroaryl-C 1-4 Alkyl-carbonyl-amino, heteroaryl-C 1-4 Alkyl-amino-carbonyl-C 1-4 Alkyl, Heteroaryl-C 1-4 Alkyl-carbonyl-amino-C 1-4 Alkyl, heterocyclyl, heterocyclyl-C 1-4 Alkyl, heterocyclic-C 1-4 Alkoxy, phenyl, or phenyl-C 1-4 Alkoxy,
[0045] Wherein the heteroaryl group is a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure group, wherein one or more carbon atom ring members are replaced by one or more heteroatoms (e.g., O, S or N atoms) where the structural stability permits,
[0046] wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O and S, and
[0047] wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1 or 2 substituents, each substituent selected from R3;
[0048] R2 is halogen, hydroxy, cyano, oxo, hydroxy-imino, C 1-4 Alkyl, halo-C 1-4 Alkyl, amino, C 1-4 Alkyl-amino, (C 1-4alkyl)2-amino, amino-C 1-4 Alkyl, amino-carbonyl, hydroxy-C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Alkoxy-carbonyl, C 2-4 Alkenyl, C 3-7 Cycloalkyl or heterocyclyl-C 1-4 alkyl;
[0049] R3 is halogen, hydroxy, nitro, oxo, hydroxy-imino, C 1-4 Alkyl, halo-C 1-4 Alkyl, amino, C 1-4 Alkyl-amino, (C 1-4 alkyl)2-amino, amino-C 1-4 Alkyl, C 1-4 Alkyl-amino-C 1-4 Alkyl, (C 1-4 Alkyl)2-amino-C 1-4 Alkyl, amino-carbonyl, C 1-4 Alkyl-amino-carbonyl, C 1-4 Alkyl-amino-carbonyl-C 1-4 Alkyl, C 1-4 Alkyl-carbonyl-amino, C 1-4 Alkyl-carbonyl-amino-C 1-4 Alkyl, Hydroxyl-C 1-4 Alkyl, C 1-4 Alkyl-carbonyl, C 1-4 Alkoxy, halo-C 1-4 Alkoxy, amino-C 1-4 Alkoxy, Hydroxyl-C 1-4 Alkoxy, C 1-4 Alkyl-C 1-4 Alkoxy, C 1-4 Alkyl-amino-C 1-4 Alkoxy, (C 1-4 alkyl)2-amino-C 1-4 Alkoxy, C 1-4 Alkyl-carbonyl-amino-C 1-4 Alkoxy, C 1-4 Alkoxy-C 1-4 Alkoxy, C 1-4 Alkoxy-carbonyl, C 1-4 Alkoxy-carbonyl-amino, C 1-4 Alkoxy-carbonyl-amino-C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkenyl-amino-carbonyl, C 3-7 Cycloalkyl, C 3-7 Cycloalkyl-C 1-4Alkoxy, C 3-7 Cycloalkenyl, heteroaryl, heteroaryl-C 1-4 Alkyl, Heteroaryl-C 1-4 Alkyl-amino, heteroaryl-C 1-4 Alkyl-amino-carbonyl, heteroaryl-C 1-4 Alkyl-carbonyl-amino, heteroaryl-C 1-4 Alkyl-amino-carbonyl-C 1-4 Alkyl, Heteroaryl-C 1-4 Alkyl-carbonyl-amino-C 1-4 Alkyl, heterocyclyl, heterocyclyl-C 1-4 Alkyl, phenyl, or phenyl-C 1-4 Alkoxy;
[0050] R4 is independently selected from halogen, C 1-4 Alkyl, Hydroxyl-C 1-4 Alkyl, amino, C 1-4 Alkyl-amino, (C 1-4 alkyl) 2-amino, or hydroxy-C 1-4 Alkyl-amino; and
[0051] R5 is hydrogen, C 1-4 Alkyl, or hydroxy-C 1-4 alkyl;
[0052] wherein the form of the compound is selected from the group consisting of: its prodrug form, salt form, hydrate form, solvate form, clathrate form, isotopologue form, racemate form, enantiomer form, diastereoisomer form, stereoisomer form, polymorph form and tautomer form.
[0053] Another embodiment of the present invention is also directed to a method for treating or ameliorating HD in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of formula (I) or a form thereof, wherein the compound of formula (I) is selected from the compounds of formula (Ia) and formula (Ib):
[0054]
[0055] in
[0056] X is O, NH, N(CH3) or a bond;
[0057] A is an aryl group, a heteroaryl group or a heterocyclic group,
[0058] wherein the aryl group is selected from the group consisting of:
[0059]
[0060] wherein the heteroaryl group is selected from the group consisting of:
[0061]
[0062]
[0063] Wherein the heterocyclic group is selected from the group consisting of:
[0064]
[0065] B is a heterocyclic group selected from the group consisting of:
[0066]
[0067] Where available valence permits, R 1a , R 1b and R 1c Each is one or more substituents selected from the following: halogen, hydroxyl, cyano, C 1-4 Alkyl, halogenated C 1-4 Alkyl, amino, C 1-4 Alkyl-amino, (C 1-4 alkyl)2-amino, amino-C 1-4 Alkyl, C 1-4 Alkyl-amino-C 1-4 Alkyl, (C 1-4 alkyl)2-amino-C 1-4 Alkyl, amino-carbonyl, C 1-4 Alkyl-amino-carbonyl, (C 1-4 alkyl) 2-amino-carbonyl, C 1-4 Alkyl-amino-carbonyl-C 1-4 Alkyl, (C 1-4 alkyl)2-amino-carbonyl-C 1-4 Alkyl, C 1-4 Alkyl-carbonyl-amino, C 1-4 Alkyl-carbonyl-amino-C 1-4 Alkyl, Hydroxyl-C 1-4 Alkyl, C 1-4 Alkyl-carbonyl, C 1-4 Alkoxy, halo-C 1-4 Alkoxy, amino-C 1-4 Alkoxy, Hydroxyl-C 1-4 Alkoxy, C 1-4 Alkyl-C 1-4 Alkoxy, C 1-4 Alkyl-amino-C 1-4 Alkoxy, (C 1-4 Alkyl)2-amino-C 1-4 Alkoxy, C 1-4 Alkyl-carbonyl-amino-C 1-4 Alkoxy, C1-4 Alkoxy-C 1-4 Alkoxy, C 1-4 Alkoxy-carbonyl, C 1-4 Alkoxy-carbonyl-amino, C 1-4 Alkoxy-carbonyl-amino-C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkenyl-amino-carbonyl, C 3-7 Cycloalkyl, C 3-7 Cycloalkyl-C 1-4 Alkoxy, C 3-7 Cycloalkenyl, heteroaryl, heteroaryl-C 1-4 Alkyl, Heteroaryl-C 1-4 Alkyl-amino, heteroaryl-C 1-4 Alkyl-amino-carbonyl, heteroaryl-C 1-4 Alkyl-carbonyl-amino, heteroaryl-C 1-4 Alkyl-amino-carbonyl-C 1-4 Alkyl, Heteroaryl-C 1-4 Alkyl-carbonyl-amino-C 1-4 Alkyl, heterocyclyl, heterocyclyl-C 1-4 Alkyl, heterocyclic-C 1-4 Alkoxy, phenyl, or phenyl-C 1-4 Alkoxy,
[0068] Wherein the heteroaryl group is a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure group, wherein one or more carbon atom ring members are replaced by one or more heteroatoms (e.g., O, S or N atoms) where the structural stability permits,
[0069] wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O and S, and
[0070] wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1 or 2 substituents, each substituent selected from R3;
[0071] Where available valence permits, R 2a , R 2b and R 2c Each is one or more substituents selected from the following: halogen, hydroxy, cyano, oxo, hydroxy-imino, C 1-4 Alkyl, halo-C 1-4 Alkyl, amino, C 1-4 Alkyl-amino, (C 1-4 alkyl)2-amino, amino-C 1-4 Alkyl, C 1-4 Alkyl-amino-C 1-4Alkyl, (C 1-4 Alkyl)2-amino-C 1-4 Alkyl, amino-carbonyl, hydroxy-C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Alkoxy-carbonyl, C 2-4 Alkenyl, C 3-7 Cycloalkyl or heterocyclic-C 1-4 alkyl,
[0072] wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2 or 3 heteroatom ring members selected from N, O and S, and
[0073] wherein each instance of heterocyclyl is optionally substituted with 1 or 2 substituents, each substituent selected from R3;
[0074] R3 is halogen, hydroxy, nitro, oxo, hydroxy-imino, C 1-4 Alkyl, amino, C 1-4 Alkyl-amino, (C 1-4 alkyl)2-amino, amino-C 1-4 Alkyl, C 1-4 Alkyl-amino-C 1-4 Alkyl, (C 1-4 alkyl)2-amino-C 1-4 Alkyl, amino-carbonyl, C 1-4 Alkyl-amino-carbonyl, (C 1-4 alkyl) 2-amino-carbonyl, C 1-4 Alkyl-amino-carbonyl-C 1-4 Alkyl, (C 1-4 alkyl)2-amino-carbonyl-C 1-4 Alkyl, C 1-4 Alkyl-carbonyl-amino, C 1-4 Alkyl-carbonyl-amino-C 1-4 Alkyl, Hydroxyl-C 1-4 Alkyl, C 1-4 Alkyl-carbonyl, C 1-4 Alkoxy, halo-C 1-4 Alkoxy, amino-C 1-4 Alkoxy, Hydroxyl-C 1-4 Alkoxy, C 1-4 Alkyl-C 1-4 Alkoxy, C 1-4 Alkyl-amino-C 1-4 Alkoxy, (C 1-4 alkyl)2-amino-C 1-4 Alkoxy, C 1-4 Alkyl-carbonyl-amino-C 1-4 Alkoxy, C 1-4Alkoxy-C 1-4 Alkoxy, C 1-4 Alkoxy-carbonyl, C 1-4 Alkoxy-carbonyl-amino, C 1-4 Alkoxy-carbonyl-amino-C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkenyl-amino-carbonyl, C 3-7 Cycloalkyl, C 3-7 Cycloalkyl-C 1-4 Alkoxy, C 3-7 Cycloalkenyl, heteroaryl, heteroaryl-C 1-4 Alkyl, Heteroaryl-C 1-4 Alkyl-amino, heteroaryl-C 1-4 Alkyl-amino-carbonyl, heteroaryl-C 1-4 Alkyl-carbonyl-amino, heteroaryl-C 1-4 Alkyl-amino-carbonyl-C 1-4 Alkyl, Heteroaryl-C 1-4 Alkyl-carbonyl-amino-C 1-4 Alkyl, heterocyclyl, heterocyclyl-C 1-4 Alkyl, phenyl, or phenyl-C 1-4 Alkoxy; and
[0075] R 4a , R 4b , R 4c , R 4d , R 4e , R 4f and R 4g independently selected from halogen, C 1-4 Alkyl, Hydroxyl-C 1-4 Alkyl, amino, C 1-4 Alkyl-amino, (C 1-4 alkyl) 2-amino, or hydroxy-C 1-4 Alkyl-amino;
[0076] wherein the form of the compound is selected from the group consisting of: its prodrug form, salt form, hydrate form, solvate form, clathrate form, isotopologue form, racemate form, enantiomer form, diastereoisomer form, stereoisomer form, polymorph form and tautomer form.
[0077] Another aspect of the present invention relates to a compound of formula (I) or a form thereof, wherein the compound of formula (I) is selected from a compound of formula (Ia11), a compound of formula (Ia15), a compound of formula (Ia18) or a compound of formula (Ib1):
[0078]
[0079] where (when present),
[0080] X is selected from O, NR5 or a bond;
[0081] A is selected from phenyl, thienyl, indazolyl, pyridyl, pyrimidinyl or phenoxy, wherein phenyl and phenoxy are each optionally substituted with 1, 2 or 3 substituents, each of which is selected from R 1a ,
[0082] wherein thienyl, indazolyl, pyridyl, pyrimidinyl are each optionally substituted by 1 or 2 substituents, each of which is selected from R 1a ,
[0083] B is selected from 1H-pyrazolyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, (1R,5S)-8-azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]oct-2-enyl, 2,6-diazaspiro[3.4]octyl, or 2,7-diazaspiro[3.5]nonyl, each optionally substituted with 1 or 2 substituents, each of which is selected from R 4a ;
[0084] R 1a Selected from halogen, hydroxyl, C 1-4 Alkyl, halo-C 1-4 Alkyl, amino, C 1-4 alkoxy or heteroaryl,
[0085] Wherein the heteroaryl group is a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure group, wherein, where the structural stability permits, one or more carbon atom ring members are replaced by one or more heteroatoms (e.g., O, S or N atoms), optionally substituted by 1 or 2 substituents, each of which is selected from R 3a ;
[0086] R 3a Selected from nitro or C 1-4 Alkyl; and,
[0087] R 4a It is C 1-4 alkyl;
[0088] R 5a It is hydrogen, C 1-4 Alkyl, or hydroxy-C 1-4 alkyl;
[0089] wherein the form of the compound is selected from the group consisting of: its prodrug form, salt form, hydrate form, solvate form, clathrate form, isotopologue form, racemate form, enantiomer form, diastereoisomer form, stereoisomer form, polymorph form and tautomer form.
[0090] Another aspect of the present invention relates to a compound of formula (I) or a form thereof, wherein the compound of formula (I) is selected from a compound of formula (Ia11), a compound of formula (Ia15), a compound of formula (Ia18) or a compound of formula (Ib1):
[0091] where (when present),
[0092] R 1a is selected from fluorine, chlorine, hydroxy, methyl, difluoromethyl, amino, methoxy or 1H-pyrazolyl or 1H-imidazol-1-yl,
[0093] wherein 1H-pyrazolyl is optionally substituted by 1 or 2 substituents, each substituent being selected from R 3a ;
[0094] R 3a is selected from nitro or methyl or amino; and,
[0095] R 4a is methyl or ethyl;
[0096] R 5a is hydrogen or methyl;
[0097] wherein the form of the compound is selected from the group consisting of: its prodrug form, salt form, hydrate form, solvate form, clathrate form, isotopologue form, racemate form, enantiomer form, diastereoisomer form, stereoisomer form, polymorph form and tautomer form.
[0098] Another embodiment of the method of the present invention includes the use of a compound of formula (Ia) or a form thereof (selected from a compound of formula (Ia1) or a form thereof), wherein the substituent R 1a , R 1b and X (when present) as shown in the table below, with multiple substituents separated by commas; and "--" indicates that one or more R is absent 1a , R 1b and X substituent:
[0099]
[0100]
[0101]
[0102] Another embodiment of the method of the present invention includes the use of a compound of formula (Ia) or a form thereof (selected from a compound of formula (Ia2) or a form thereof), wherein the substituent R 1a , R 1b and R 4a(when present) as shown in the table below, with multiple substituents separated by commas; and "--" indicates the absence of one or more R 1a , R 1b and R 4a Substituents:
[0103]
[0104]
[0105]
[0106]
[0107] Another embodiment of the method of the present invention includes the use of a compound of formula (Ia) or a form thereof (selected from a compound of formula (Ia3) or a form thereof), wherein the substituent R 1a , R 1b and X (when present) as shown in the table below, with multiple substituents separated by commas; and "--" indicates that one or more R is absent 1a , R 1b and X substituent:
[0108]
[0109]
[0110] Another embodiment of the method of the present invention includes the use of a compound of formula (Ia) or a form thereof (selected from a compound of formula (Ia4) or a form thereof), wherein the substituents X, R 1a , R 1b and R 4a (when present) as shown in the table below, with multiple substituents separated by commas; and "--" indicates the absence of one or more X, R 1a , R 1b and R 4a Substituents:
[0111]
[0112]
[0113]
[0114] Another embodiment of the method of the present invention includes the use of a compound of formula (Ia) or a form thereof (selected from a compound of formula (Ia5) or a form thereof), wherein the substituent R 1a and R 1b (when present) as shown in the table below, with multiple substituents separated by commas; and "--" indicates the absence of one or more R1a and R 1b Substituents:
[0115]
[0116]
[0117] Another embodiment of the method of the present invention includes the use of a compound of formula (Ia) or a form thereof (selected from a compound of formula (Ia6) or a form thereof), wherein the substituent R 1a (when present) as shown in the following table; and, "--" indicates the absence of one or more R 1a Substituents:
[0118]
[0119] Compound <![CDATA[R 1a ]]> 239 -- 246 <![CDATA[2,3-(CH3)2]]> 247 <![CDATA[2-CH3]]> 248 <![CDATA[3-CH3]]>
[0120] Another embodiment of the method of the present invention includes the use of a compound of formula (Ia) or a form thereof (selected from a compound of formula (Ia7) or a form thereof), wherein the substituent R 1a (when present) as shown in the following table; and, "--" indicates the absence of one or more R 1a Substituents:
[0121]
[0122] Compound <![CDATA[R 1a ]]> 258 -- 260 <![CDATA[2-CH3]]>
[0123] Another embodiment of the method of the present invention includes the use of a compound of formula (Ia) or a form thereof (selected from a compound of formula (Ia8) or a form thereof), wherein the substituent R 1a and B (when present) are as shown in the following table; and "--" indicates the absence of one or more R 1a and B substituent:
[0124]
[0125] Compound <![CDATA[R 1a ]]> B 209 -- <![CDATA[6-((3aR,6aS)-5-CH3-Hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)]]> 269 2-CN Piperazine-1-yl
[0126] Another embodiment of the method of the present invention includes the use of a compound of formula (Ia) or a form thereof (selected from a compound of formula (Ia9) or a form thereof), wherein the substituent R 1a and B (when present) are as shown in the following table; and "--" indicates the absence of one or more R 1a and B substituent:
[0127]
[0128] Compound <![CDATA[R 1a ]]> B 214 -- <![CDATA[6-((3aR,6aS)-5-CH3-Hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)]]> 270 -- Piperazine-1-yl 291 <![CDATA[3-CH3]]> Piperazine-1-yl
[0129] Another embodiment of the method of the present invention includes the use of a compound of formula (Ia) or a form thereof (selected from a compound of formula (Ia10) or a form thereof), wherein the substituent R 1a and B (when present) are as shown in the following table; and "--" indicates the absence of one or more R 1a and B substituent:
[0130]
[0131] Compound <![CDATA[R 1a ]]> B 268 2-CN Piperazine-1-yl 271 -- 1,2,3,6-Tetrahydropyridin-4-yl
[0132] Another embodiment of the method of the present invention includes the use of a compound of formula (Ia) or a form thereof (selected from a compound of formula (Ia11) or a form thereof), wherein the substituents A, X and R 4a (when present) as shown in the following table; and, "--" indicates that one or more of A, X and R are absent. 4a Substituents:
[0133]
[0134]
[0135]
[0136]
[0137] Another embodiment of the present invention includes compounds of formula (Ia) or forms thereof (selected from compounds of formula (Ia11) or forms thereof), wherein the substituents A, X and R 4a (when present) as shown in the following table; and, "--" indicates that one or more of A, X and R are absent. 4a Substituents:
[0138]
[0139] Compound A X 420 <![CDATA[2 - OCH3 - 4 - (4 - NO2 - 1H - pyrazol - 1 - yl)phenyl]]> <![CDATA[N(CH3)]]> 428 <![CDATA[2,5-F2-4-(1H-pyrazol-4-yl)phenyl]]> <![CDATA[N(CH3)]]> 430 <![CDATA[2,3-F2-4-(1H-pyrazol-4-yl)phenyl]]> <![CDATA[N(CH3)]]> 431 <![CDATA[2,5-F2-4-(1H-pyrazol-4-yl)phenyl]]> O 434 <![CDATA[2-OCH3-4-(1H-pyrazol-4-yl)phenyl]]> <![CDATA[N(CH3)]]> 435 4-(1H-pyrazol-4-yl)phenyl O 437 2-F-4-(1H-pyrazol-4-yl)phenyl O 438 <![CDATA[4-(1-CH3-1H-pyrazol-4-yl)thiophen-2-yl]]> O 440 2-F-4-OH-phenyl <![CDATA[N(CH3)]]> 442 <![CDATA[2-CH3-2H-indazol-5-yl]]> <![CDATA[N(CH3)]]> 443 <![CDATA[2-CH3-2H-indazol-5-yl]]> O 444 <![CDATA[4-Chloro-2-methoxyphenyl]]> O 445 <![CDATA[2-CH3-pyrazolo[1,5-a]pyridin-3-yl]]> <![CDATA[N(CH3)]]> 446 Imidazolo[1,2-a]pyridin-6-yl O 447 <![CDATA[2 - OCH3 - 4 - (1H - pyrazol - 1 - yl)phenyl]]> O 448 5-(1H-pyrazol-4-yl)thiophen-2-yl O 449 <![CDATA[5-(1-CH3-1H-pyrazol-4-yl)thiophen-2-yl]]> O 450 4-(1H-pyrazol-4-yl)thiophen-2-yl O 451 <![CDATA[2-OH-4-[3,5-(CH3)2-1H-pyrazol-4-yl]phenyl]]> O 452 2-F-4-(1H-pyrazol-4-yl)phenyl <![CDATA[N(CH3)]]> 453 <![CDATA[2 - OCH3 - 4 - OH - phenyl]]> O 454 <![CDATA[2 - OCH3 - 4 - (4 - NO2 - 1H - pyrazol - 1 - yl)phenyl]]> O 455 <![CDATA[2,4-(OH)2-phenyl]]> O 456 2-Cl-4-(1H-pyrazol-4-yl)phenyl <![CDATA[N(CH3)]]> 457 5-amino-2-(1H-pyrazol-4-yl)pyrimidin-4-yl O 458 <![CDATA[2,6-F2-4-(1H-pyrazol-4-yl)phenyl]]> O 464 <![CDATA[2-(CHF2)-4-(1H-pyrazol-4-yl)phenyl]]> O 465 <![CDATA[2-(CHF2)-4-(1H-pyrazol-4-yl)phenyl]]> <![CDATA[N(CH3)]]>
[0140] Another embodiment of the method of the present invention includes the use of a compound of formula (Ia) or a form thereof (selected from a compound of formula (Ia11) or a form thereof), wherein the substituents A, X and R 4a (when present) as shown in the following table; and, "--" indicates that one or more of A, X and R are absent. 4a Substituents:
[0141]
[0142] Compound A X 420 <![CDATA[2 - OCH3 - 4 - (4 - NO2 - 1H - pyrazol - 1 - yl)phenyl]]> <![CDATA[N(CH3)]]> 428 <![CDATA[2,5-F2-4-(1H-pyrazol-4-yl)phenyl]]> <![CDATA[N(CH3)]]> 430 <![CDATA[2,3-F2-4-(1H-pyrazol-4-yl)phenyl]]> <![CDATA[N(CH3)]]> 431 <![CDATA[2,5-F2-4-(1H-pyrazol-4-yl)phenyl]]> O 434 <![CDATA[2-OCH3-4-(1H-pyrazol-4-yl)phenyl]]> <![CDATA[N(CH3)]]> 435 4-(1H-pyrazol-4-yl)phenyl O 437 2-F-4-(1H-pyrazol-4-yl)phenyl O 438 <![CDATA[4-(1-CH3-1H-pyrazol-4-yl)thiophen-2-yl]]> O 440 2-F-4-OH-phenyl <![CDATA[N(CH3)]]> 442 <![CDATA[2-CH3-2H-indazol-5-yl]]> <![CDATA[N(CH3)]]> 443 <![CDATA[2-CH3-2H-indazol-5-yl]]> O 444 <![CDATA[4-Chloro-2-methoxyphenyl]]> O 445 <![CDATA[2-CH3-pyrazolo[1,5-a]pyridin-3-yl]]> <![CDATA[N(CH3)]]> 446 Imidazolo[1,2-a]pyridin-6-yl O 447 <![CDATA[2-OCH3-4-(1H-pyrazol-1-yl)phenyl]]> O 448 5-(1H-pyrazol-4-yl)thiophen-2-yl O 449 <![CDATA[5-(1-CH3-1H-pyrazol-4-yl)thiophen-2-yl]]> O 450 4-(1H-pyrazol-4-yl)thiophen-2-yl O 451 <![CDATA[2-OH-4-[3,5-(CH3)2-1H-pyrazol-4-yl]phenyl]]> O 452 2-F-4-(1H-pyrazol-4-yl)phenyl <![CDATA[N(CH3)]]> 453 <![CDATA[2 - OCH3 - 4 - OH - phenyl]]> O 454 <![CDATA[2 - OCH3 - 4 - (4 - NO2 - 1H - pyrazol - 1 - yl)phenyl]]> O 455 <![CDATA[2,4-(OH)2-phenyl]]> O 456 2-Cl-4-(1H-pyrazol-4-yl)phenyl <![CDATA[N(CH3)]]> 457 5-amino-2-(1H-pyrazol-4-yl)pyrimidin-4-yl O 458 <![CDATA[2,6-F2-4-(1H-pyrazol-4-yl)phenyl]]> O 464 <![CDATA[2-(CHF2)-4-(1H-pyrazol-4-yl)phenyl]]> O 465 <![CDATA[2-(CHF2)-4-(1H-pyrazol-4-yl)phenyl]]> <![CDATA[N(CH3)]]>
[0143] Another embodiment of the method of the present invention includes the use of a compound of formula (Ia) or a form thereof (selected from a compound of formula (Ia12) or a form thereof), wherein the substituents X, R 1a and B (when present) are as shown in the following table; and, "--" indicates the absence of one or more X, R 1a and B substituent:
[0144]
[0145] Compound <![CDATA[R 1a ]]> X B 66 H NH Azetidin-3-yl 82 OH -- Piperazine-1-yl 85 H -- 1,2,3,6-Tetrahydropyridin-4-yl 86 OH -- 1,2,3,6-Tetrahydropyridin-4-yl 87 OH -- 2,2,6,6-Tetramethyl-(1,2,3,6-tetrahydropyridin-4-yl) 88 OH -- <![CDATA[1-CH3-(1,2,3,6-tetrahydropyridin-4-yl)]]> 89 OH -- Piperidin-4-yl 99 H <![CDATA[CH2]]> Piperidin-4-yl
[0146] Another embodiment of the method of the present invention includes the use of a compound of formula (Ia) or a form thereof (selected from a compound of formula (Ia13) or a form thereof), wherein the substituents X, R 1a and R 4a (when present) as shown in the following table; and, "--" indicates that one or more X, R are not present 1a and R 4a Substituents:
[0147]
[0148]
[0149]
[0150] Another embodiment of the method of the present invention includes the use of a compound of formula (Ia) or a form thereof (selected from a compound of formula (Ia14) or a form thereof), wherein the substituents X and B (when present) are as shown in the following table; and "--" indicates the absence of one or more of the X and B substituents:
[0151]
[0152] Compound X B 55 O Piperidin-4-yl 56 O <![CDATA[(2S,4R,6R)-2,6-(CH3)2-piperidin-4-yl]]> 57 O <![CDATA[2,6-(CH3)2-piperidin-4-yl]]> 58 O Pyrrolidin-3-yl 59 O <![CDATA[2-CH3-piperidin-4-yl]]> 60 <![CDATA[OCH2]]> 1H-Pyrrolidin-3-yl 61 O 3-F-Piperidin-4-yl 65 -- Piperazine-1-yl 67 NH Azetidin-3-yl 68 -- <![CDATA[3,5-(CH3)2-piperazin-1-yl]]> 69 -- <![CDATA[7-CH3-2,7-diazaspiro[4.4]non-2-yl]]> 70 -- [1,4]diazepine-1-yl 71 -- <![CDATA[4-CH2CH2OH-piperazin-1-yl]]> 72 -- 2,7-Diazaspiro[3.5]nonan-7-yl 73 -- 2,7-Diazaspiro[3.5]nonan-7-yl 74 -- <![CDATA[3-CH2OH-piperazin-1-yl]]> 75 -- 1,7-Diazaspiro[4.4]nonan-7-yl 76 -- <![CDATA[4-NH2-4-CH3-piperidin-1-yl]]> 77 -- <![CDATA[3-N(CH3)2-piperidin-1-yl]]> 79 -- <![CDATA[3,3-(CH3)2-piperazin-1-yl]]> 80 -- <![CDATA[7-CH2CH2OH-2,7-diazaspiro[4.4]non-2-yl]]> 83 -- 1,2,3,6-Tetrahydropyridin-4-yl 84 -- Piperidin-4-yl 102 O <![CDATA[(6S)-6-[(S)-CH(OH)CH3]-2,2-(CH3)2-piperidin-4-yl]]> 133 O <![CDATA[2,2-(CH3)2-piperidin-4-yl]]>
[0153] Another embodiment of the method of the present invention includes the use of a compound of formula (Ia) or a form thereof (selected from a compound of formula (Ia15) or a form thereof), wherein the substituents X, R 1a and R 4a (when present) as shown in the following table; and, "--" indicates that one or more X, R are not present 1a and R 4a Substituents:
[0154]
[0155]
[0156]
[0157] Another embodiment of the present invention includes compounds of formula (Ia) or forms thereof (selected from compounds of formula (Ia15) or forms thereof), wherein the substituents X, R 1a and R 4a (when present) as shown in the following table; and, "--" indicates that one or more X, R are not present 1a and R 4a Substituents:
[0158]
[0159] Compound X <![CDATA[R 1a ]]> <![CDATA[R 4a ]]> 413 NH 1H-pyrazol-4-yl -- 414 O <![CDATA[1-CH3-1H-pyrazol-4-yl]]> -- 416 <![CDATA[N(CH3)]]> <![CDATA[5-CH3-1H-pyrazol-4-yl]]> -- 417 O 1H-Imidazol-1-yl -- 418 O <![CDATA[5-CH3-1H-pyrazol-4-yl]]> -- 419 <![CDATA[N(CH3)]]> <![CDATA[4-Nitro-1H-pyrazol-1-yl]]> -- 421 O <![CDATA[5-NH2-1H-pyrazol-1-yl]]> -- 423 O <![CDATA[4-Nitro-1H-pyrazol-1-yl]]> -- 460 <![CDATA[N(CH3)]]> 1H-pyrazol-4-yl -- 461 O 1H-pyrazol-4-yl --
[0160] Another embodiment of the method of the present invention includes the use of a compound of formula (Ia) or a form thereof (selected from a compound of formula (Ia15) or a form thereof), wherein the substituents X, R 1a and R 4a (when present) as shown in the following table; and, "--" indicates that one or more X, R are not present 1a and R 4a Substituents:
[0161]
[0162] Compound X <![CDATA[R 1a ]]> 413 NH 1H-pyrazol-4-yl 414 O <![CDATA[1-CH3-1H-pyrazol-4-yl]]> 416 <![CDATA[N(CH3)]]> <![CDATA[5-CH3-1H-pyrazol-4-yl]]> 417 O 1H-Imidazol-1-yl 418 O <![CDATA[5-CH3-1H-pyrazol-4-yl]]> 419 <![CDATA[N(CH3)]]> <![CDATA[4-Nitro-1H-pyrazol-1-yl]]> 421 O <![CDATA[5-NH2-1H-pyrazol-1-yl]]> 423 O <![CDATA[4-Nitro-1H-pyrazol-1-yl]]> 460 <![CDATA[N(CH3)]]> 1H-pyrazol-4-yl 461 O 1H-pyrazol-4-yl
[0163] Another embodiment of the method of the present invention includes the use of a compound of formula (Ia) or a form thereof (selected from a compound of formula (Ia16) or a form thereof), wherein the substituent R 1a and R 4a (when present) as shown in the following table; and, "--" indicates the absence of one or more R 1a and R 4a Substituents:
[0164]
[0165] Compound <![CDATA[R 1a ]]> <![CDATA[R 4a ]]> 81 1H-pyrazol-1-yl -- 199 1H-pyrazol-4-yl <![CDATA[(CH2)2OH]]> 200 1H-pyrazol-4-yl -- 201 1H-pyrazol-4-yl <![CDATA[CH3]]> 202 <![CDATA[4-(1-CH3-pyridin-2(1H)-one)]]> <![CDATA[CH3]]> 203 <![CDATA[4-(1-CH3-pyridin-2(1H)-one)]]> <![CDATA[CH3]]>
[0166] Another embodiment of the method of the present invention includes the use of a compound of formula (Ia) or a form thereof (selected from a compound of formula (Ia17) or a form thereof), wherein the substituent R 1a (when present) as shown in the following table; and, "--" indicates the absence of one or more R 1a Substituents:
[0167]
[0168] Compound <![CDATA[R 1a ]]> 204 1H-pyrazol-4-yl 205 <![CDATA[4-(1-CH3-pyridin-2(1H)-one)]]>
[0169] Another embodiment of the present invention includes a compound of formula (Ia) or a form thereof (selected from a compound of formula (Ia18) or a form thereof), wherein the substituents X and B (when present) are as shown in the following table; and "--" indicates the absence of one or more of the X and B substituents:
[0170]
[0171] Compound X B 411 <![CDATA[N(CH3)]]> (1R,5S)-8-Azabicyclo[3.2.1]octan-3-yl 412 NH (1R,5S)-8-Azabicyclo[3.2.1]octan-3-yl 415 O (1R,5S)-8-Azabicyclo[3.2.1]octan-3-yl 422 -- <![CDATA[1-CH3-(1,2,3,6-tetrahydropyridin-4-yl)]]> 424 -- 1,2,3,6-Tetrahydropyridin-4-yl 425 -- <![CDATA[1-CH3CH2-(1,2,3,6-tetrahydropyridin-4-yl)]]> 425 <![CDATA[N(CH3)]]> Piperidin-4-yl 427 NH Piperidin-4-yl 429 -- 8-Azabicyclo[3.2.1]oct-2-en-3-yl 432 O Piperidin-4-yl 433 NH (1R,5S)-8-Azabicyclo[3.2.1]octan-3-yl 436 O <![CDATA[2,6-(CH3)2-piperidin-4-yl]]> 439 -- 2,7-diazaspiro[3.5]nonan-2-yl 441 O <![CDATA[2,6-(CH3)2-piperidin-4-yl]]> 459 -- 2,6-diazaspiro[3.5]octan-2-yl
[0172] Another embodiment of the method of the present invention includes the use of a compound of formula (Ia) or a form thereof (selected from a compound of formula (Ia18) or a form thereof), wherein the substituents X, R 1a and B (when present) are as shown in the following table; and, "--" indicates the absence of one or more X, R 1a and B substituent:
[0173]
[0174]
[0175]
[0176] Another embodiment of the method of the present invention includes the use of a compound of formula (Ib) or a form thereof (selected from a compound of formula (Ib1) or a form thereof), wherein the substituent A is as shown in the following table:
[0177]
[0178] Compound A 302 6-(Naphthyl-2-ol) 320 6-(Naphthalene-2,7-diol) 331 <![CDATA[7-OCH3-quinolin-6-yl]]> 332 7-OH-quinolin-6-yl 337 <![CDATA[2-CN-7-OCH3-quinolin-6-yl]]> 355 3-F-5-(1H-pyrazol-4-yl)-pyridin-2-yl 364 <![CDATA[2-(6-OCH3-3,4-dihydroisoquinolin-1(2H)-one)]]> 392 6-OH-1-oxo-2,3-dihydro-1H-inden-5-yl 401 <![CDATA[3-(4-OCH3-1-CH3-quinolin-1(2H)-one)]]> 402 <![CDATA[3-(4-Hydroxy-1-methylquinolin-1(2H)-one)]]> 403 3-(Quinolin-2(1H)-one) 404 <![CDATA[3-(1-Methoxyquinolin-2(1H)-one)]]> 408 5-CN-Benzo[b]thiophen-2-yl 409 5-Cl-Benzo[b]thiophen-2-yl
[0179] Another embodiment of the present invention includes a compound of formula (Ib) or a form thereof (selected from a compound of formula (Ib1) or a form thereof), wherein the substituent A is as shown in the following table:
[0180] Compound A 462 3-(1H-pyrazol-4-yl)phenoxy 463 4-(1H-pyrazol-4-yl)phenoxy
[0181] Another embodiment of the method of the present invention includes the use of a compound of formula (Ib) or a form thereof (selected from a compound of formula (Ib1) or a form thereof), wherein the substituent A is as shown in the following table:
[0182]
[0183] Compound A 462 3-(1H-pyrazol-4-yl)phenoxy 463 4-(1H-pyrazol-4-yl)phenoxy
[0184] Another embodiment of the method of the present invention includes the use of a compound of formula (Ib) or a form thereof (selected from a compound of formula (Ib2) or a form thereof), wherein the substituent A is as shown in the following table:
[0185]
[0186] Compound A 321 6-Naphthalene-2,7-diol
[0187] Another embodiment of the method of the present invention includes the use of a compound of formula (Ib) or a form thereof (selected from a compound of formula (Ib3) or a form thereof), wherein the substituent R 1a , R 1b and B (when present) are as shown in the following table; and "--" indicates the absence of one or more R 1a , R 1b and B substituent:
[0188]
[0189]
[0190]
[0191] Another embodiment of the present invention includes the use of a compound of formula (Ib) or a form thereof (selected from a compound of formula (Ib4) or a form thereof), wherein the substituent R 1a , R 1b , R 1c , R 1d (each representing a range of R1) and X (when present) are shown in the following table; and, "--" indicates the absence of one or more R 1a , R 1b , R 1c , R 1d and X substituent:
[0192]
[0193]
[0194]
[0195]
[0196] Another embodiment of the method of the present invention includes the use of a compound of formula (Ib) or a form thereof (selected from a compound of formula (Ib5) or a form thereof), wherein the substituent R 1a , R 1b , R 1c , R 1d (each represents the range of R1) and R 4a (when present) as shown in the following table; and, "--" indicates the absence of one or more R 1a , R 1b , R 1c , R 1d and R 4a Substituents:
[0197]
[0198] Compound <![CDATA[R 1a ]]> <![CDATA[R 1b ]]> <![CDATA[R 1c ]]> <![CDATA[R 1d ]]> <![CDATA[R 4a ]]> 353 1H-pyrazol-4-yl F F H -- 362 1H-pyrazol-4-yl <![CDATA[OCH3]]> H F <![CDATA[CH3]]> 370 1H-Imidazol-1-yl Cl H H <![CDATA[CH3]]> 379 <![CDATA[1-CH3-1H-pyrazol-4-yl]]> Cl H H <![CDATA[CH3]]> 380 1H-pyrazol-4-yl Cl H H <![CDATA[CH3]]> 384 1H-pyrazol-4-yl F H H <![CDATA[CH3]]> 396 1H-pyrazol-4-yl F H OH -- 405 1H-pyrazol-4-yl Cl H H --
[0199] Another embodiment of the method of the present invention includes the use of a compound of formula (Ib) or a form thereof (selected from a compound of formula (Ib6) or a form thereof), wherein the substituent R 1a , R 1b , R 1c and R 1d (each represents a range of R1) (when present) as shown in the following table; and, "--" indicates the absence of one or more R 1a , R 1b , R 1c and R 1d Substituents:
[0200]
[0201] Compound <![CDATA[R 1a ]]> <![CDATA[R 1b ]]> <![CDATA[R 1c ]]> <![CDATA[R 1d ]]> 386 <![CDATA[1-CH3-1H-pyrazol-4-yl]]> <![CDATA[OCH3]]> H H 395 <![CDATA[1-CH3-1H-pyrazol-4-yl]]> OH H H 399 1H-pyrazol-4-yl H F F 400 1H-pyrazol-4-yl OH H F
[0202] Another embodiment of the method of the present invention includes the use of a compound of formula (Ib) or a form thereof (selected from a compound of formula (Ib7) or a form thereof), wherein the substituent R 1b (when present) as shown in the following table:
[0203]
[0204] Compound <![CDATA[R 1b ]]> 304 <![CDATA[OCH3]]> 322 OH
[0205] Another embodiment of the method of the present invention includes the use of a compound of formula (Ib) or a form thereof (selected from a compound of formula (Ib8) or a form thereof), wherein the substituent R 1b (when present) as shown in the following table:
[0206]
[0207] Compound <![CDATA[R 1b ]]> 303 <![CDATA[OCH3]]> 323 OH
[0208] Embodiments of the use of a compound of formula (I) or a form thereof include a method of using a compound of formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of formula (I) or a form thereof selected from the group consisting of:
[0209]
[0210]
[0211]
[0212]
[0213]
[0214]
[0215]
[0216]
[0217]
[0218]
[0219]
[0220]
[0221]
[0222]
[0223]
[0224]
[0225]
[0226]
[0227]
[0228]
[0229]
[0230]
[0231]
[0232]
[0233]
[0234]
[0235]
[0236]
[0237]
[0238]
[0239]
[0240]
[0241]
[0242]
[0243]
[0244]
[0245]
[0246]
[0247]
[0248]
[0249]
[0250]
[0251]
[0252]
[0253]
[0254] Wherein, the form of the compound is selected from the group consisting of: its prodrug form, salt form, hydrate form, solvate form, inclusion compound form, isotopologue form, racemate form, enantiomer form, diastereomer form, stereoisomer form, polymorph form and tautomer form.
[0255] In another aspect, the compound of formula (I) or a form thereof comprises a compound selected from the group consisting of:
[0256]
[0257]
[0258]
[0259]
[0260]
[0261]
[0262] Wherein, the form of the compound is selected from the group consisting of: its prodrug form, salt form, hydrate form, solvate form, inclusion compound form, isotopologue form, racemate form, enantiomer form, diastereomer form, stereoisomer form, polymorph form and tautomer form.
[0263] Another embodiment of the use of a compound of formula (I) or a form thereof includes a method of using a compound of formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of formula (I) or a form thereof selected from the group consisting of: 1 ) indicates the isolated salt form):
[0264]
[0265]
[0266]
[0267]
[0268]
[0269]
[0270]
[0271]
[0272]
[0273]
[0274]
[0275]
[0276]
[0277] Wherein, the form of the compound is selected from the group consisting of: its prodrug form, salt form, hydrate form, solvate form, inclusion compound form, isotopologue form, racemate form, enantiomer form, diastereomer form, stereoisomer form, polymorph form and tautomer form.
[0278] In one aspect, the compound of Formula (I) or a form thereof comprises a compound selected from the group consisting of:
[0279]
[0280]
[0281] Wherein, the form of the compound is selected from the group consisting of: its prodrug form, salt form, hydrate form, solvate form, inclusion compound form, isotopologue form, racemate form, enantiomer form, diastereomer form, stereoisomer form, polymorph form and tautomer form.
[0282] Another embodiment of the use of a salt of a compound of formula (I) or a form thereof includes a method of using a salt of a compound of formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, the method comprising administering to the subject an effective amount of a salt of a compound of formula (I) or a form thereof selected from the group consisting of:
[0283]
[0284]
[0285] Wherein, the form of the compound salt is selected from the group consisting of: its prodrug form, hydrate form, solvate form, inclusion form, isotopologue form, racemate form, enantiomer form, diastereomer form, stereoisomer form, polymorph form and tautomer form.
[0286] In one aspect, the salt of the compound of formula (I) or a form thereof comprises a compound selected from the group consisting of:
[0287]
[0288]
[0289] Wherein, the form of the compound salt is selected from the group consisting of: its prodrug form, hydrate form, solvate form, inclusion form, isotopologue form, racemate form, enantiomer form, diastereomer form, stereoisomer form, polymorph form and tautomer form.
[0290] Another embodiment of the present invention includes a method of using a compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I) or a form thereof.
[0291] Another embodiment of the present invention includes a method of using a compound of formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, the method comprising administering to the subject an effective amount of a salt of a compound of formula (I) or a form thereof.
[0292] Another embodiment of the present invention includes the use of a compound of formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of a compound of formula (I) or a form thereof.
[0293] Another embodiment of the present invention includes the use of a salt of a compound of formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering to the subject an effective amount of a salt of a compound of formula (I) or a form thereof.
[0294] Chemical Definition
[0295] As used herein, the term “C 1-4 "Alkyl" generally refers to a saturated hydrocarbon group having one to four carbon atoms in a straight or branched configuration, including but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, etc. In some embodiments, C 1-4 Alkyl groups include C 1-3 Alkyl, C 1-2 Alkyl, etc. Where available valence permits, C 1-4 Alkyl groups may be optionally substituted.
[0296] As used herein, the term “C 2-6 "Alkenyl" generally refers to partially unsaturated hydrocarbon groups having two to five carbon atoms in a linear or branched configuration and having one or more carbon-carbon double bonds, including but not limited to vinyl, allyl, propenyl, etc. In some embodiments, C 2-6 Alkenyl includes C 2-4 Alkenyl, C 2-3 Where available valence permits, C 2-6 An alkenyl group can be optionally substituted.
[0297] As used herein, the term “C 1-4 "Alkoxy" generally refers to a group having the formula -OC 1-4 The alkyl group is a saturated hydrocarbon group of one to four carbon atoms in a straight or branched configuration, including but not limited to methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, etc. In some embodiments, C 1-4 Alkoxy includes C 1-3 Alkoxy, C 1-2 Alkoxy, etc. Where available valence permits, C 1-4 An alkoxy group may be optionally substituted.
[0298] As used herein, the term “C 3-14 "Cycloalkyl" generally refers to a saturated monocyclic, bicyclic or polycyclic hydrocarbon group, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 1H-indanyl, indenyl, tetrahydronaphthyl, etc. In some embodiments, C 3-14 Cycloalkyl includes C 3-10 Cycloalkyl, C 3-8 Cycloalkyl, C 3-7 Cycloalkyl, C 5-8 Cycloalkyl, C 9-10 Cycloalkyl, etc. Where available valence permits, C 3-14 Cycloalkyl groups can be optionally substituted.
[0299] As used herein, the term “C 3-14 "Cycloalkenyl" generally refers to partially unsaturated monocyclic, bicyclic or polycyclic hydrocarbon groups having one or more chemically stable carbon-carbon double bonds, including but not limited to cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, etc. In some embodiments, C 3-14 Cycloalkenyl groups include C 3-7 Cycloalkenyl, C 3-8 Cycloalkenyl, C 5-8 Cycloalkenyl, C 3-10 Cycloalkenyl, etc. Where available valence permits, C 3-14 A cycloalkenyl group may be optionally substituted.
[0300] As used herein, the term "aryl" generally refers to a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure group, including but not limited to phenyl, naphthyl, anthracenyl, fluorenyl, azulenyl, phenanthrenyl, etc. Aryl groups may be optionally substituted where available valences permit.
[0301] As used herein, the term "heteroaryl" generally refers to a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structural group, wherein one or more carbon atom ring members are replaced by one or more heteroatoms (e.g., O, S or N atoms) where structural stability permits, including but not limited to furanyl, thienyl (also known as phenylthio), pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyranyl, thiopyranyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, indolyl, indazolyl, indolizinyl, benzofuranyl, benzothiophenyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, 9H-purinyl, quinoxalinyl, isoindolyl, quinolyl, isoquinolyl, quinazoline 1,4-dihydroindeno[1,2-c]-1H-pyrazolyl, 2,3-dihydro-1H-inden-1-one, 2,3-dihydro-1H-indenyl, 3,4-dihydroquinolin-2(1H)-one, 5,6-dihydroimidazole, 1,2-a-pyridyl, 1,5-a-pyridyl, ...2-a-pyridyl, 1,4-dihydroindeno[1,2-c]-1H-pyrazolyl, 2,3-dihydro-1H-inden-1-one, 2,3-dihydro-1H oxazolo[5,1-a]isoquinolinyl, 8H-indeno[1,2-d]thiazolyl, benzo[c][1,2,5]oxadiazolyl, benzo[d]oxazol-2(3H)-one, quinolin-2(1H)-one, quinazolin-4(1H)-one, quinazolin-2,4(1H,3H)-dione, benzo-[d]oxazolyl, pyrazolo[1,5-a]pyridinyl, etc. Heteroaryl groups may be optionally substituted on carbon or nitrogen ring members as permitted by available valences.
[0302] As used herein, the term "heterocyclyl" generally refers to a saturated or partially unsaturated monocyclic, bicyclic or polycyclic carbon atom ring structural group, wherein one or more carbon atom ring members are replaced by heteroatoms (e.g., O, S or N atoms) where structural stability permits, including but not limited to oxirane, oxetanyl, azetidinyl, dihydrofuranyl, tetrahydrofuranyl, dihydrothiophenyl, tetrahydrothiophenyl, pyrrolinyl, pyrrolidinyl, dihydropyrazolyl, pyrazolinyl, pyrazolidinyl, dihydroimidazolyl, imidazolinyl, imidazolidinyl, isoxazolinyl, isoxazolidinyl, isothiazolinyl, isothiazolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, triazolinyl, triazolidinyl, oxadiazolinyl, oxadiazolidinyl, thiadiazolinyl, thiazolidinyl, diazolidinyl, tetrazolinyl, tetrazolidinyl, dihydro-2H-pyranyl, dihydropyridinyl, tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl, hexahydropyridinyl, dihydropyrimidinyl, tetrahydropyrimidinyl, 1,4,5,6-tetrahydropyrimidinyl, dihydropyrazinyl, tetrahydropyrazinyl, dihydropyridazinyl, tetrahydropyridazinyl, piperazinyl, piperidinyl, morpholinyl, thiomorpholinyl, dihydrotriazinyl, tetrahydrotriazinyl, hexahydrotriazinyl, 1,4-diazepanyl, dihydroindolinyl, indolinyl, tetrahydroindolinyl, dihydroindazolyl, tetrahydroindazolyl, dihydroisoindolyl, dihydrobenzofuranyl, tetrahydrobenzofuranyl, dihydrobenzothienyl, tetrahydrobenzothienyl, dihydrobenzimidazolyl, tetrahydrobenzimidazolyl, dihydrobenzoxazolyl, 2,3- dihydrobenzo[d]oxazolyl, tetrahydrobenzoxazolyl, dihydrobenzoxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, tetrahydrobenzoxazinyl, benzo[1,3]dioxolyl, benzo[1,4]dioxanyl, dihydropurinyl, tetrahydropurinyl, dihydroquinolyl, tetrahydroquinolyl, 1,2,3,4-tetrahydroquinolyl, dihydro Hydroisoquinolyl, 3,4-dihydroisoquinolinyl-(1H)-yl, tetrahydroisoquinolyl, 1,2,3,4-tetrahydroisoquinolyl, dihydroquinazolinyl, tetrahydroquinazolinyl, dihydroquinoxalinyl, tetrahydroquinoxalinyl, 1,2,3,4-tetrahydroquinoxalinyl, 1,3-dioxolanyl, 2,5-dihydro-1H-pyrrolyl, 4,5-dihydro-1H-imidazolyl , tetrahydro-2H-pyranyl, hexahydropyrrolo[3,4-b][1,4]oxazin-(2H)-yl, (4aR,7aS)-hexahydropyrrolo[3,4-b][1,4]oxazin-(4aH)-yl, 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl, (cis)-octahydrocyclopenta[c]pyrrolyl, hexahydropyrrolo[3,4-b][1,4]oxazin-(4aH)-yl Hydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, 5H-pyrrolo[3,4]-b]pyridin-(7H)-yl, 5,7-dihydro-6H-pyrrolo[3,4-b]pyridinyl, tetrahydro-1H-pyrrolo[3,4-b]pyridin-(2H,7H,7aH)-yl, hexahydro-1H-pyrrolo[3,4-b]pyridin-(2H)-yl, (4aR,7aR)-hexahydro-1H-pyrrolo[3,4-b]pyridin-(2H)-yl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, 2,3,4,9-tetrahydro-1H-carbazolyl, 1,2,3,4-tetrahydropyrazino[1,2-a]indolyl, 2,3-dihydro-1H-pyrrolo[1,2-a]indolyl, (3aR,6aR)-hexahydrocyclopenta[c]pyrrol-(1H)-yl , (3aR,4R,6aS)-hexahydrocyclopenta[c]pyrrol-(1H)-yl, (3aR,4S,6aS)-hexahydrocyclopenta[c]pyrrol-(1H)-yl, (3aR,5r,6aS)-hexahydrocyclopenta[c]pyrrol-(1H)-yl, 1,3-dihydro-2H-isoindolyl, octahydro-2H-isoindolyl, (3aS)-1,3,3a,4,5,6-hexahydro-2H-isoindolyl, (3aR,4R,7aS)-1H-isoindol-(3H,3aH,4H,5H,6H,7H,7aH)-yl, (3aR,7aS)-octahydro-2H- isoindolyl, (3aR,4R,7aS)-octahydro-2H-isoindolyl, (3aR,4S,7aS)-octahydro-2H-isoindolyl, 2,5-diazabicyclo[2.2.1]heptyl, 2-azabicyclo[2.2.1]heptenyl, 3-azabicyclo[3.1.0]hexyl, 3,6-diazabicyclo[3.1.0]hexyl, (1R,5S)-3-azabicyclo[3.1.0]hexyl, (1S,5R)-3-azabicyclo[3.2.0]heptyl, 5-azaspiro[2.4]heptyl, 2,6-diazaspiro[3.3]heptyl, 2,5-diazaspiro[3.4]octyl, 2, 6-diazaspiro[3.4]octyl, 2,7-diazaspiro[3.5]nonyl, 2,7-diazaspiro[4.4]nonyl, 2-azaspiro[4.5]decyl, 2,8-diazaspiro[4.5]decyl, 3,6-diazabicyclo[3.2.1]octyl, 1,4-dihydroindeno[1,2-c]pyrazolyl, dihydropyranyl, dihydropyridinyl, dihydroquinolinyl, 8H-indeno[1,2-d]thiazolyl, tetrahydroimidazo[1,2-a]pyridinyl, pyridin-2(1H)-one, (1R,5S)-8-azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]oct-2-enyl, and the like. The heterocyclic group may be optionally substituted on carbon or nitrogen ring members as permitted by available valences.
[0303] As used herein, the term “C 2-4 "Alkenyl-amino-carbonyl" refers to a radical of the formula: -C(=O)-NH-C2-4 Alkenyl.
[0304] As used herein, the term “C 1-4 Alkoxy-C 1-4 "Alkoxy" refers to a radical of the formula: -OC 1-4 Alkyl-OC 1-4 alkyl.
[0305] As used herein, the term “C 1-4 "Alkoxy-carbonyl" refers to a radical of the formula: -C(=O)-OC 1-4 alkyl.
[0306] As used herein, the term “C 1-4 "Alkoxy-carbonyl-amino" refers to a radical of the formula: -NH-C(=O)-OC 1-4 alkyl.
[0307] As used herein, the term “C 1-4 Alkoxy-carbonyl-amino-C 1-4 "Alkoxy" refers to a radical of the formula: -OC 1-4 Alkyl-NH-C(=O)-OC 1-4 alkyl.
[0308] As used herein, the term “C 1-4 Alkyl-C 1-4 "Alkoxy" refers to a radical of the formula: -OC 1-4 Alkyl-C 1-4 alkyl.
[0309] As used herein, the term “C 1-4 "Alkyl-amino" refers to a radical of the formula: -NH-C 1-4 alkyl.
[0310] As used herein, the term “ 1-4 "alkyl)2-amino" refers to a radical of the formula: -N(C 1-4 Alkyl)2.
[0311] As used herein, the term “C 1-4 Alkyl-amino-C 1-4 "Alkoxy" refers to a radical of the formula: -OC 1-4 Alkyl-NH-C 1-4 alkyl.
[0312] As used herein, the term “ 1-4 alkyl)2-amino-C 1-4 "Alkoxy" refers to a radical of the formula: -OC 1-4 Alkyl-N(C 1-4 Alkyl)2.
[0313] As used herein, the term “C 1-4 Alkyl-amino-C 1-4 "Alkyl" refers to a radical of the formula: -C 1-4 Alkyl-NH-C 1-4 alkyl.
[0314] As used herein, the term “ 1-4 alkyl)2-amino-C 1-4 "Alkyl" refers to a radical of the formula: -C 1-4 Alkyl-N(C 1-4 Alkyl)2.
[0315] As used herein, the term “C 1-4 "Alkyl-amino-carbonyl" refers to a radical of the formula: -C(=O)-NH-C 1-4 alkyl.
[0316] As used herein, the term “ 1-4 "alkyl)2-amino-carbonyl" refers to a radical of the formula: -C(=O)-N(C 1-4 Alkyl)2.
[0317] As used herein, the term “C 1-4 Alkyl-amino-carbonyl-C 1-4 "Alkyl" refers to a radical of the formula: -C 1-4 Alkyl-C(=O)-NH-C 1-4 alkyl.
[0318] As used herein, the term “ 1-4 alkyl)2-amino-carbonyl-C 1-4 "Alkyl" refers to a radical of the formula: -C 1-4 Alkyl-C(=O)-N(C 1-4 Alkyl)2.
[0319] As used herein, the term “C 1-4 "Alkyl-carbonyl" refers to a radical of the formula: -C(=O)-C 1-4 alkyl.
[0320] As used herein, the term “C 1-4 "Alkyl-carbonyl-amino" refers to a radical of the formula: -NH-C(=O)-C 1-4 alkyl.
[0321] As used herein, the term “C 1-4 Alkyl-carbonyl-amino-C 1-4 "Alkoxy" refers to a radical of the formula: -OC 1-4 Alkyl-NH-C(=O)-C 1-4 alkyl.
[0322] As used herein, the term “C 1-4 Alkyl-carbonyl-amino-C 1-4 "Alkyl" refers to a radical of the formula: -C 1-4 Alkyl-NH-C(=O)-C 1-4 alkyl.
[0323] As used herein, the term "amino" refers to a radical of the formula: -NH2.
[0324] As used herein, the term "amino-C 1-4 "Alkoxy" refers to a radical of the formula: -OC 1-4 Alkyl-NH2.
[0325] As used herein, the term "amino-C 1-4 "Alkyl" refers to a radical of the formula: -C 1-4 Alkyl-NH2.
[0326] As used herein, the term "amino-carbonyl" refers to a radical of the formula: -C(=O)-NH2.
[0327] As used herein, the term "cyano" refers to a radical of the formula: -CN.
[0328] As used herein, the term “C 3-7 Cycloalkyl-C 1-4 "Alkoxy" refers to a radical of the formula: -OC 1-4 Alkyl-C 3-7 Cycloalkyl.
[0329] As used herein, the term "halo-C 1-4 "Alkoxy" refers to a radical of the formula: -OC 1-4 Alkyl-halo, where available valence permits, C 1-4 The alkyl group may be partially or completely substituted with one or more halogen atoms. 1-4 Alkoxy includes halo-C 1-6 Alkoxy, halo-C 1-4 Alkoxy, etc.
[0330] As used herein, the term "halo-C 1-4 "Alkyl" refers to a radical of the formula: -C 1-4 Alkyl-halo, where available valence permits, C 1-4 The alkyl group may be partially or completely substituted with one or more halogen atoms. 1-4 Alkyl groups include halo-C 1-6 Alkyl, halo-C 1-4 Alkyl, etc.
[0331] As used herein, the term "heteroaryl-C 1-4 "Alkyl" refers to a radical of the formula: -C 1-4 Alkyl-heteroaryl.
[0332] As used herein, the term "heteroaryl-C 1-4 "Alkyl-amino" refers to a radical of the formula: -NH-C 1-4 Alkyl-heteroaryl.
[0333] As used herein, the term "heteroaryl-C 1-4 "Alkyl-amino-carbonyl" refers to a radical of the formula: -C(=O)-NH-C 1-4 Alkyl-heteroaryl.
[0334] As used herein, the term "heteroaryl-C 1-4 Alkyl-amino-carbonyl-C 1-4 "Alkyl" refers to a radical of the formula: -C 1-4 Alkyl-C(=O)-NH-C 1-4 Alkyl-heteroaryl.
[0335] As used herein, the term "heteroaryl-C 1-4 "Alkyl-carbonyl-amino" refers to a radical of the formula: -NH-C(=O)-C 1-4 Alkyl-heteroaryl.
[0336] As used herein, the term "heteroaryl-C 1-4 Alkyl-carbonyl-amino-C 1-4 "Alkyl" refers to a radical of the formula: -C 1-4 Alkyl-NH-C(=O)-C 1-4 Alkyl-heteroaryl.
[0337] As used herein, the term "heterocyclyl-C 1-4 "Alkoxy" refers to a radical of the formula: -C 1-4 Alkoxy-heterocyclyl.
[0338] As used herein, the term "heterocyclyl-C 1-4 "Alkyl" refers to a radical of the formula: -C 1-4 Alkyl-heterocyclyl.
[0339] As used herein, the term "hydroxy" refers to a radical of the formula: -OH.
[0340] As used herein, the term "hydroxy-C 1-4 "Alkoxy" refers to a radical of the formula: -OC 1-4 Alkyl-OH, where available valence permits, C 1-4 The alkyl group may be partially or fully substituted with one or more hydroxyl groups.
[0341] As used herein, the term "hydroxy-C 1-4 "Alkyl" refers to a radical of the formula: -C 1-4 Alkyl-OH, where available valence permits, C 1-4 The alkyl group may be partially or fully substituted with one or more hydroxyl groups.
[0342] As used herein, the term "hydroxy-C 1-4 "Alkyl-amino" refers to a radical of the formula: -NH-C 1-4 Alkyl-OH, where available valence permits, C 1-4 The alkyl group may be partially or fully substituted with one or more hydroxyl groups.
[0343] As used herein, the term "hydroxy-imino" refers to a =NOH group of formula C(=NOH).
[0344] As used herein, the term "oxo" refers to a radical of the formula: C=O.
[0345] As used herein, the term "phenyl-C 1-4 "Alkoxy" refers to a radical of the formula: -C 1-4 Alkoxy-phenyl.
[0346] As used herein, the term "substituent" refers to a positional variant on an atom of a core molecule substituted at a designated atomic position, which replaces one or more hydrogens at a designated atom, provided that the normal valence of the designated atom is not exceeded, and the substitution produces a stable compound. This combination is permitted only when a combination of substituents and / or variants produces a stable compound. It should be noted by those skilled in the art that any carbon and heteroatom with a valence that does not appear to be satisfied as described or shown herein is assumed to have a sufficient number of hydrogen atoms to satisfy the valence described or shown. In some cases, in a substituted group, one or more substituents with double bonds (e.g., "oxo" or "=O") as a point of attachment may be described, displayed, or listed herein, wherein the structure may only show a single bond as a point of attachment to the core structure of formula (I). It will be understood by those skilled in the art that, although only single bonds are shown, double bonds are also meant for those substituents.
[0347] As used herein, with reference to the definitions of chemical terms provided herein, the term "etc." means variations of chemical structures that would be expected by one skilled in the art, including but not limited to isomers (including isomers of chain, branched or positional structures), hydration of ring systems (including saturation or partial unsaturation of monocyclic, bicyclic or polycyclic ring structures), and all other variations that produce stable compounds as permitted by available valences.
[0348] For the purposes of this specification, when one or more substituent variants of a compound of formula (I) or a form thereof include functional groups incorporated into the compound of formula (I), each functional group occurring at any position within the disclosed compound may be independently selected and independently and / or optionally substituted (where appropriate).
[0349] As used herein, the term "independently selected" or "individually selected" refers to a functional variant in a list of substituents that can appear more than once on a structure of Formula (I), with the substitution pattern at each occurrence being independent of any other occurrence. In addition, the use of generic substituent variants on any formula or structure of the compounds described herein should be understood to include replacement of generic substituents with species included in the specific genus, for example, an aryl group can be replaced with a phenyl or naphthyl group, etc., and the resulting compounds are included within the scope of the compounds described herein.
[0350] As used herein, when in a phrase (e.g., "... 3-14 Cycloalkyl, C 3-14 Cycloalkyl-C 1-4 Alkyl, Aryl, Aryl-C 1-4 Alkyl, Heteroaryl, Heteroaryl-C 1-4 Alkyl, heterocyclyl and heterocyclyl-C 1-4 alkyl), the term "each instance of" or "in each instance (when present)" means C 3-14 Cycloalkyl, aryl, heteroaryl and heterocyclyl ring systems (when each occurs alone or as a substituent).
[0351] As used herein, the term "optionally substituted" refers to optional substitution with a specified substituent variant, group, radical, or moiety.
[0352] Compound form
[0353] As used herein, the term "form" refers to a compound of formula (I) having a form selected from the group consisting of its free acid form, free base form, prodrug form, salt form, hydrate form, solvate form, inclusion compound form, isotopologue form, racemic form, enantiomeric form, diastereomeric form, stereoisomer form, polymorphic form and tautomeric form.
[0354] In certain embodiments described herein, the compound of Formula (I) is in the form of a free acid, a free base, or a salt thereof.
[0355] In certain embodiments described herein, the compound of Formula (I) is in the form of a salt thereof.
[0356] In certain embodiments described herein, the compound of Formula (I) is in the form of an isotopologue thereof.
[0357] In certain embodiments described herein, the compound of Formula (I) is in the form of a stereoisomer, racemate, enantiomer or diastereomer thereof.
[0358] In certain embodiments described herein, the compounds of Formula (I) are in the form of tautomers thereof.
[0359] In certain embodiments described herein, the form of the compound of Formula (I) is a pharmaceutically acceptable form.
[0360] In certain embodiments described herein, the compound of Formula (I) or a form thereof is isolated for use.
[0361] As used herein, the term "isolated" refers to the physical state of a compound of formula (I) or a form thereof after separation and / or purification from a synthetic process (e.g., from a reaction mixture) or a natural source, or a combination thereof, according to separation or purification methods described herein or methods well known to those skilled in the art (e.g., chromatography, recrystallization, etc.), and its purity is sufficient to be characterized by standard analytical techniques described herein or well known to those skilled in the art.
[0362] As used herein, the term "protected" refers to a functional group in a compound of formula (I) or a form thereof that is in a modified form to prevent undesirable side reactions at the protected site when the compound is reacted. Suitable protecting groups are recognized by those skilled in the art and reference standard textbooks (e.g., TW Greene et al., Protective Groups in organic Synthesis (1991), Wiley, New York). These functional groups include hydroxyl, phenolic, amino and carboxylic acid. Suitable protecting groups for hydroxyl or phenolic groups include trialkylsilyl or diarylalkylsilyl (e.g., tert-butyldimethylsilyl, tert-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, substituted benzyl, methyl, methoxymethanol, etc. Suitable protecting groups for amino, amidino and guanidino groups include tert-butyloxycarbonyl, benzyloxycarbonyl, etc. Suitable protecting groups for carboxylic acids include alkyl esters, aryl esters or aralkyl esters. In some cases, the protecting group may also be a polymer resin, such as Wang resin or 2-chlorotrityl chloride resin. Protecting groups can be added or removed according to standard techniques well known to those skilled in the art and as described herein. It will also be appreciated by those skilled in the art that, although such protected derivatives of the compounds described herein may not themselves be pharmacologically active, they can be administered to a subject and then metabolized in vivo to form pharmacologically active compounds described herein. Therefore, these derivatives can be described as "prodrugs". All prodrugs of the compounds described herein are included within the scope of the uses described herein.
[0363] As used herein, the term "prodrug" refers to a form of the instant compound (e.g., a drug precursor) that is converted in vivo to produce an active compound of formula (I) or a form thereof. The conversion can occur by various mechanisms (e.g., by metabolic and / or non-metabolic chemical processes), such as hydrolysis and / or metabolism in the blood, liver, and / or other organs and tissues. A discussion of the use of prodrugs is provided below: T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems", American Chemical Society Seminar Series Vol. 14, and Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
[0364] In one example, when the compound of formula (I) or its form contains a carboxylic acid functional group, the prodrug may include an ester formed by replacing the hydrogen atom of the acid group with a functional group (e.g., an alkyl group, etc.). In another example, when the compound of formula (I) or its form contains a hydroxyl functional group, the prodrug form may be prepared by replacing the hydrogen atom of the hydroxyl group with another functional group (e.g., an alkyl group, an alkylcarbonyl group, or a phosphonate, etc.). In another example, when the compound of formula (I) or its form contains an amine functional group, the prodrug form may be prepared by replacing the hydrogen atom of one or more amines with a functional group (e.g., an alkyl group or a substituted carbonyl group). Pharmaceutically acceptable prodrugs of the compound of formula (I) or its form include those compounds substituted by one or more of the following groups: carboxylate, sulfonate, amino acid ester, phosphonate, and monophosphate, diphosphate, or triphosphate or alkyl substituent (when appropriate). As described herein, it should be understood by those skilled in the art that one or more of these substituents may be used to provide a compound of formula (I) or its form as a prodrug.
[0365] One or more compounds described herein may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents (eg, water, ethanol, etc.), and the description herein is intended to include both solvated and unsolvated forms.
[0366] As used herein, the term "solvate" refers to a physical association of a compound described herein with one or more solvent molecules. The physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In some cases, the solvate is capable of separation, such as when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid. As used herein, "solvate" includes both solution phase and separable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like.
[0367] As used herein, the term "hydrate" refers to a solvate wherein the solvent molecule is water.
[0368] Formula (I) compounds can form salts, which are intended to be included within the scope of this specification. Unless otherwise indicated, the formula (I) compounds or forms thereof mentioned herein should be understood to include reference to their salt forms. The term "salt" as used herein means an acid salt formed with an inorganic acid and / or an organic acid, and a basic salt formed with an inorganic base and / or an organic base. In addition, when the formula (I) compound or a form thereof contains a basic moiety (such as, but not limited to, an amine moiety) and an acidic moiety (such as, but not limited to, a carboxylic acid), a zwitterion ("inner salt") can be formed and is included in the term "salt" as used herein.
[0369] As used herein, the term "pharmaceutically acceptable salts" refers to those salts of the compounds described herein that are safe and effective (i.e., non-toxic, physiologically acceptable) and biologically active for use in mammals, although other salts are also useful. Salts of compounds of formula (I) can be formed, for example, by reacting a compound of formula (I) or a form thereof with an amount of an acid or base (e.g., an equal amount) in a medium (e.g., a medium in which the salt is precipitated), or in an aqueous medium followed by lyophilization.
[0370] Pharmaceutically acceptable salts include salts of one or more acidic or basic groups present in the compounds described herein. Embodiments of acid addition salts include, but are not limited to, acetate, ascorbate, benzoate, benzenesulfonate, bisulfate, bitartrate, borate, bromide, butyrate, chloride, citrate, camphorate, camphorsulfonate, ethanesulfonate, formate, fumarate, gentisate, gluconate, glucuronate, glutamate, iodide, isonicotinate, lactate, maleate, mesylate, napsylate, nitrate, oxalate, pamoate, pantothenate, phosphate, propionate, sugar acid salt, salicylate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate (also known as toluenesulfonate), trifluoroacetate, etc. Certain embodiments of acid addition salts include chloride, dichloride, trichloride, bromide, acetate, formate or trifluoroacetate.
[0371] In addition, acids generally considered suitable for forming pharmaceutically useful salts from basic drug compounds are discussed below: for example, P. Stahl et al., Camille G. (ed.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al., Journal of Pharmaceutical Sciences (1977) 66 (1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33, 201-217; Anderson et al., The Practice of Medicinal Chemistry (1996), Academic Press, New York; and The Orange Book (U.S. Food and Drug Administration website, Washington, D.C.). The disclosures of these are incorporated herein by reference.
[0372] Suitable basic salts include, but are not limited to, aluminum, ammonium, calcium, lithium, magnesium, potassium, sodium, and zinc salts.
[0373] All such acid salts and base salts are intended to be included within the scope of pharmaceutically acceptable salts as described herein. In addition, for the purposes of this specification, all such acid salts and base salts are considered equivalent to the free forms of the corresponding compounds.
[0374] The compounds of formula (I) and forms thereof may also exist in tautomeric forms. All such tautomeric forms are contemplated and intended to be included within the scope of the compounds of formula (I) or forms thereof as described herein.
[0375] The compounds of formula (I) or forms thereof may contain asymmetric or chiral centers and therefore exist in different stereoisomeric forms. The present specification is intended to include all stereoisomeric forms of the compounds of formula (I) and mixtures thereof, including racemic mixtures.
[0376] The compounds described herein may include one or more chiral centers and may therefore exist as racemic mixtures (R / S) or as substantially pure enantiomers and diastereomers. The compounds may also exist as substantially pure (R) or (S) enantiomers (when there is one chiral center). In one embodiment, the compounds described herein are (S) isomers and may exist as enantiomerically pure compositions (substantially containing only (S) isomers). In another embodiment, the compounds described herein are (R) isomers and may exist as enantiomerically pure compositions (substantially containing only (R) isomers). As will be appreciated by those skilled in the art, when there is more than one chiral center, the compounds described herein may also exist as (R,R) isomers, (R,S) isomers, (S,R) isomers, or (S,S) isomers as defined by IUPAC nomenclature.
[0377] As used herein, the term "substantially pure" refers to a compound consisting essentially of greater than or equal to 90% of a single isomer, greater than or equal to 92% of a single isomer, greater than or equal to 95% of a single isomer, greater than or equal to 98% of a single isomer, greater than or equal to 99% of a single isomer, or equal to 100% of a single isomer.
[0378] In one aspect of the specification, the compound of formula (I) or a form thereof is in substantially pure (S) enantiomeric form, which is present in an amount greater than or equal to 90%, an amount greater than or equal to 92%, an amount greater than or equal to 95%, an amount greater than or equal to 98%, an amount greater than or equal to 99%, or an amount equal to 100%.
[0379] In one aspect of the specification, the compound of formula (I) or a form thereof is in substantially pure (R) enantiomeric form, which is present in an amount greater than or equal to 90%, an amount greater than or equal to 92%, an amount greater than or equal to 95%, an amount greater than or equal to 98%, an amount greater than or equal to 99%, or an amount equal to 100%.
[0380] As used herein, a "racemate" is any mixture of isomeric forms that is not "enantiomerically pure," including, for example but not limited to, mixtures in ratios of about 50 / 50, about 60 / 40, about 70 / 30, or about 80 / 20.
[0381] In addition, this specification includes all geometric isomers and positional isomers. For example, if the compound of formula (I) or its form contains double bonds or fused rings, the cis form and trans form and mixture are all included in the scope of this specification. The diastereomeric mixture can be separated into their respective diastereomers based on their physicochemical differences by methods well known to those skilled in the art (e.g., by chromatography and / or fractional crystallization). Enantiomers can be separated by using chiral HPLC columns or other chromatographic methods known to those skilled in the art. Enantiomers can also be separated by reacting with appropriate optically active compounds (e.g., chiral auxiliary agents, such as chiral alcohols or Mosher acid chlorides) to convert enantiomeric mixtures into diastereomeric mixtures, separate diastereomers and convert (e.g., hydrolyze) each diastereomer to the corresponding pure enantiomer. In addition, some of the compounds of formula (I) can be atropisomers (e.g., substituted biaryl) and are considered to be part of the present invention.
[0382] All stereoisomers (e.g., geometric isomers, optical isomers, etc.) of the compounds of the present invention (including salts, solvates, esters and prodrugs of the compounds and salts, solvates and esters of the prodrugs), such as those existing due to asymmetric carbon atoms on various substituents, including enantiomeric forms (even in the absence of asymmetric carbons), rotational isomers, atropisomers and diastereomeric forms, are also included within the scope of the present invention, as are positional isomers (e.g., 4-pyridyl and 3-pyridyl). Each stereoisomer of the compounds described herein may, for example, be substantially free of other isomers, or may be present in a racemic mixture as described above.
[0383] The use of the terms "salt," "solvate," "ester," "prodrug," and the like are intended to apply equally to the salts, solvates, esters, and prodrugs of enantiomers, stereoisomers, rotational isomers, tautomers, positional isomers, racemates, or isotopomers of the compounds of the invention.
[0384] The term "isotopologue" refers to isotopically enriched compounds described herein that are identical to those described herein but for the fact that one or more atoms are replaced by atoms having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that may be incorporated into the compounds described herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, such as 2 H. 3 H. 13 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S.18 F. 35 C and 36 Cl, each of which is also within the scope of the present invention.
[0385] Certain isotopically enriched compounds described herein (e.g., 3 H and 14 C-labeled) can be used in compound and / or substrate tissue distribution assays. Because tritiated (i.e., 3 H) isotopes and carbon-14 (i.e., 14 C) isotopes are particularly preferred due to their ease of preparation and detectability. In addition, heavier isotopes (e.g., deuterium (i.e. 2 H)) substitutions may offer certain therapeutic advantages due to greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and therefore may be preferred in some circumstances.
[0386] Polymorphs and amorphous forms of the compounds of formula (I) as well as salts, solvates, hydrates, esters and prodrugs of the compounds of formula (I) are further intended to be included in the present invention.
[0387] Compound Uses
[0388] The present invention relates to a method of using a compound of formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, the method comprising administering to the subject an effective amount of the compound or a form thereof.
[0389] The present invention also relates to the use of a compound of formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof.
[0390] The present invention also relates to the use of compounds of formula (I) or forms thereof active against HD.
[0391] The present invention also relates to the use of compounds of formula (I) or forms thereof in combination therapy to provide additive or synergistic activities, thereby enabling the development of combination products for the treatment or amelioration of HD.
[0392] In addition to monotherapy uses, the compounds of the present invention may be used in combination therapy with existing standard agents, possessing additive or synergistic activity with one or more known agents.
[0393] Combination therapy comprising a combination of a compound described herein and one or more known drugs can be used to treat HD, whether or not HD is responsive to known drugs.
[0394] Embodiments of the invention include the use of a compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof in combination therapy comprising administering an effective amount of a compound of Formula (I) or a form thereof and an effective amount of one or more pharmaceutical agents.
[0395] Embodiments of the invention include the use of a compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof in combination therapy comprising administering an effective amount of a compound of Formula (I) or a form thereof and an effective amount of one or more pharmaceutical agents.
[0396] In embodiments of the uses or methods provided herein, a compound of formula (I) or a form thereof used in combination with one or more additional agents can be administered to a subject or before, simultaneously with, or after administration to a subject or patient, in contact with cells of a subject or patient, or in contact with cells with another agent. A compound of formula (I) or a form thereof and an additional agent can be administered to a subject or in contact with cells in a single composition or in different compositions. In a specific embodiment, a compound of formula (I) or a form thereof is used in combination with gene therapy to inhibit HTT expression (using, for example, a viral delivery vector) or administering another small molecule HTT inhibitor. In another specific embodiment, a compound of formula (I) or a form thereof is used in combination with cell replacement using differentiated non-mutated HTT stem cells. In another specific embodiment, a compound of formula (I) or a form thereof is used in combination with cell replacement using differentiated HTT stem cells.
[0397] In one embodiment, provided herein is the use of a compound of Formula (I), or a form thereof, in combination with supportive standard of care therapy, including palliative care.
[0398] Embodiments of the invention include use of a compound of Formula (I) or a form thereof in the preparation of a kit comprising a compound of Formula (I) or a form thereof, and instructions for administering an effective amount of a compound of Formula (I) or a form thereof and an effective amount of one or more agents in a combination therapy for treating or ameliorating HD in a subject in need thereof.
[0399] Therefore, the present invention relates to the use of the compound of formula (I) or a form thereof for treating or improving HD. According to the use of the present invention, compounds that can be used to selectively treat or improve HD are identified, and the use of these compounds for treating or improving HD is provided.
[0400] One embodiment of the use of the present invention relates to the use of a compound of formula (I) or a form thereof for treating or improving HD in a subject in need thereof, which comprises administering an effective amount of a compound of formula (I) or a form thereof to the subject.
[0401] One embodiment of the use of the present invention relates to a method of using a compound of formula (I) or a form thereof to treat or improve HD in a subject in need thereof, the method comprising administering an effective amount of the compound to the subject. .
[0402] An embodiment of the use of the present invention relates to a method of using a compound of formula (I) or a form thereof to treat or improve HD in a subject in need thereof, the method comprising administering an effective amount of the compound to the subject.
[0403] An embodiment of the use of the present invention relates to the use of a compound of formula (I) or a form thereof in the preparation of a medicament for treating or ameliorating HD in a subject in need thereof, the use comprising administering an effective amount of the medicament to the subject.
[0404] An embodiment of the use of the present invention relates to the use of a compound of formula (I) or a form thereof in the preparation of a kit comprising a compound of formula (I) or a form thereof, and instructions for administering the compound to treat or ameliorate HD in a subject in need thereof.
[0405] In one aspect, for each of these embodiments, the subject is untreated. In another aspect, for each of these embodiments, the subject is treated.
[0406] As used herein, the term "treating," ...
[0407] As used herein, the term "subject" refers to an animal or any living organism that has the ability to sense and move autonomously and requires oxygen and organic food. Non-limiting examples include members of human, primate, horse, pig, cattle, murine, house mouse, canine and feline species. In some embodiments, the subject is a mammal or a warm-blooded vertebrate. In other embodiments, the subject is a human. As used herein, the term "patient" can be used interchangeably with "subject" and "human".
[0408] As used herein, the term "effective amount" or "therapeutically effective amount" refers to an amount of a compound or form of formula (I), composition or medicament thereof that effectively inhibits the above-mentioned diseases and thus produces the desired therapeutic, ameliorative, inhibitory or preventive effect in a subject in need thereof.
[0409] The dosage administered to achieve an effective target plasma concentration may also be administered based on the weight of the subject or patient. The dosage administered based on weight may be in the range of about 0.001 mg / kg / day to about 3500 mg / kg / day, or about 0.001 mg / kg / day to about 3000 mg / kg / day, or about 0.001 mg / day to about 2500 mg / kg / day, or about 0.001 mg / kg / day to about 2000 mg / kg / day, or about 0.001 mg / kg / day to about 1500 mg / kg / day, or about 0.001 mg / kg / day to about 1000 mg / kg / day, or about 0.001 mg / kg / day to about 500 mg / kg / day, or about 0.001 mg / kg / day to about 250 mg / kg / day, or about 0.001 mg / kg / day to about 100 mg / kg / day, or about 0.001 mg / kg / day to about 75 mg / kg / day, or about 0.001 mg / kg / day to about 50 mg / kg / day, or about 0.001 mg / kg / day to about 40 mg / kg / day, or about 0.001 mg / kg / day to about 30 mg / kg / day, or about 0.001 mg / kg / day to about 20 mg / kg / day, or about 0.001 mg / kg / day to about 10 mg / kg / day, or about 0.01 mg / kg / day to about 2000 mg / kg / day, or about 0.01 mg / kg / day to about 1500 mg / kg / day, or about 0.01 mg / kg / day to about 1000 mg / kg / day, or about 0.01 mg / kg / day to about 600 mg / kg / day, or about 0.01 mg / kg / day to about 500 mg / kg / day, Or about 0.01 mg / kg / day to about 300 mg / kg / day, or about 0.015 mg / kg / day to about 200 mg / kg / day, or about 0.02 mg / kg / day to about 100 mg / kg / day, or about 0.025 mg / kg / day to about 100 mg / kg / day, or about 0.03 mg / kg / day to about 100 mg / kg / day, wherein the amount is orally administered once (about once every 24 hours), twice (about once every 12 hours) or three times (about once every 8 hours) per day depending on the weight of the subject.
[0410] In certain embodiments, for patients or subjects weighing from about 40 kg to about 200 kg in a single, divided or continuous dose (for patients or subjects above or below this range, especially children under 40 kg, the dose can be adjusted), the effective amount will be in the following range: about 0.001 mg / kg / day to about 500 mg / kg / day, or about 0.01 mg / kg / day to about 500 mg / kg / day, or about 0.1 mg / kg / day to about 500 mg / kg / day, or about 1.0 mg / kg / day to about 500 mg / kg / day. Typical adult subjects are expected to have a median weight in the range of about 70 kg.
[0411] In another embodiment in which the daily dose is adjusted based on the weight of the subject or patient, the compounds described herein can be formulated at about 0.02 mg / kg / day, about 0.025 mg / kg / day, about 0.03 mg / kg / day, about 0.05 mg / kg / day, about 0.06 mg / kg / day, about 0.075 mg / kg / day, about 0.08 mg / kg / day, about 0.09 mg / kg / day, about 0.10 mg / kg / day, about 0.20 mg / kg / day, about 0.25 mg / kg / day, about 0.30 mg / kg / day, about 0.50 mg / kg / day, about 0.60 mg / kg / day, about 0.75 mg / kg / day, about 0.80 mg / kg / day, about 0.90 mg / kg / day The daily dose adjusted based on the weight of the subject or patient can be administered as a single, divided or continuous dose. In embodiments where a dose of the compound is administered more than once per day, the dose may be administered two, three, or more times per day.
[0412] Within the scope of the present invention, an "effective amount" of a compound of formula (I) or a form thereof for use in the manufacture of a medicament, for the preparation of a pharmaceutical kit, or for use in a method of treating or ameliorating HD in a subject in need thereof is intended to include an amount in the range of about 0.001 mg / kg / day to about 3500 mg / kg / day, or about 0.001 mg / kg / day to about 3000 mg / day, or about 0.001 mg / kg / day to about 2500 mg / kg / day, or about 0.001 mg / kg / day to about 2000 mg / kg / day, or about 0.001 mg / kg / day to about 1500 mg / kg / day, or about 0.001 mg / kg / day to about 2500 mg / kg / day From about 0.001 mg / kg / day to about 1000 mg / kg / day, or from about 0.001 mg / kg / day to about 500 mg / kg / day, or from about 0.001 mg / kg / day to about 250 mg / kg / day, or from about 0.001 mg / kg / day to about 100 mg / kg / day, or from about 0.001 mg / kg / day to about 75 mg / kg / day, or from about 0.001 mg / kg / day to about 50 mg / kg / day, or from about 0.001 mg / kg / day to about 40 mg / kg / day, or from about 0.001 mg / kg / day to about 30 mg / kg / day, or from about 0.001 mg / kg / day to about 50 mg / kg / day 0.001 mg / kg / day to about 20 mg / kg / day, or about 0.001 mg / kg / day to about 10 mg / kg / day, or about 0.01 mg / kg / day to about 2000 mg / kg / day, or about 0.01 mg / kg / day to about 1500 mg / kg / day, or about 0.01 mg / kg / day to about 1000 mg / kg / day, or about 0.01 mg / kg / day to about 600 mg / kg / day, or about 0.01 mg / kg / day to about 500 mg / kg / day, or about 0.01 mg / kg / day to about 300 mg / kg / day, or about 0.015 mg / kg / day to about 200 mg / kg / day, or about 0.02 mg / kg / day to about 100 mg / kg / day, or about 0.025 mg / kg / day to about 100 mg / kg / day, or about 0.03 mg / kg / day to about 100 mg / kg / day, wherein the amount is administered once (about once every 24 hours; i.e., "qd"), twice (about once every 12 hours; i.e., "bid" or "q.l2h"), three times (about once every 8 hours; i.e., "tid" or "q.8h"), or four times (about once every 6 hours; i.e., "qds", "qid" or "q.6h") per day, depending on the weight of the subject.
[0413] The amount may further include an amount within the range of about 0.001 mg to about 3500 mg per day; 0.001 mg to about 3000 mg per day; 0.001 mg to about 2500 mg per day; 0.001 mg to about 2000 mg per day; 0.001 mg to about 1500 mg per day; 0.001 mg to about 1000 mg per day; 0.001 mg to about 500 mg per day; 0.001 mg to about 250 mg per day; 1.0 mg to about 3500 mg per day; 1.0 mg to about 1500 mg per day; 1.0 mg to about 1000 mg per day; 10.0 mg to about 600 mg per day; 0.5 mg to about 2000 mg per day; or an amount within the range of about 5.0 mg to about 300 mg per day.
[0414] For example, an effective amount can be the amount required to treat HD in a subject (more specifically, a human). The effective amount for a subject will depend on various factors, including the subject's weight, size, and health. The effective amount for a given patient can be determined by routine experimentation that is within the skill and judgment of the clinician.
[0415] For any compound, the effective amount can be estimated initially in a cell culture assay or in a relevant animal model (e.g., a mouse, chimpanzee, marmoset, or tamarin animal model). The relevant animal model can also be used to determine the appropriate concentration range and route of administration. This information can then be used to determine useful doses and routes for human administration. Therapeutic efficacy and toxicity can be determined by standard pharmaceutical methods in cell cultures or experimental animals, such as EDTA. 50 (the dose that is therapeutically effective in 50% of the population) and LD 50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index and can be expressed as the ratio LD 50 / ED 50 In some embodiments, the effective amount is such that a large therapeutic index is achieved. In further embodiments, the dose is within the range of ED including little or no toxicity. 50 The dosage may vary within this range depending on the dosage form used, the sensitivity of the patient, and the route of administration.
[0416] More specifically, the concentration-biological effect relationship observed for the compound of formula (I) or a form thereof indicates that the target plasma concentration range is about 0.001 μg / mL to about 50 μg / mL, about 0.01 μg / mL to about 20 μg / mL, about 0.05 μg / mL to about 10 μg / mL, or about 0.1 μg / mL to about 5 μg / mL. For patients weighing about 10 kg to about 100 kg (for patients within this weight range (especially for children under 40 kg), the dosage can be adjusted), in order to achieve such plasma concentrations, depending on the route of administration of single, divided or continuous doses, the compounds described herein can be administered in varying doses (e.g., but not limited to, 0.1 ng to 10000 mg).
[0417] According to the factors related to the object, the accurate dosage will be determined by the practitioner. The dosage can be adjusted and applied to provide sufficient levels of the active agent or to maintain the desired effect. The factors that can be considered include the severity of the disease state, the general health of the object, race, age, body weight, sex, diet, time of the day and the frequency of application, drug combination, reaction sensitivity, experience other therapies and tolerance / reaction to the treatment. Depending on the half-life and the clearance rate of the specific preparation, the long-acting pharmaceutical composition can be applied every 2 days, every 3 days or every 4 days, applied once a week or applied once every two weeks.
[0418] The compounds and compositions described herein can be administered to a subject by any drug delivery route known in the art. Non-limiting examples include oral, ocular, rectal, buccal, topical, nasal, sublingual, transdermal, subcutaneous, intramuscular, intravenous (bolus and infusion), intracerebral, and pulmonary administration routes.
[0419] In one aspect, provided herein is a method for regulating the amount of HTT (huntingtin protein), the method comprising contacting a human cell with a compound of formula (I) or a form thereof. In a specific embodiment, provided herein is a method for regulating the amount of HTT, the method comprising contacting a human cell with a compound of formula (I) or a form thereof that regulates HTT expression. Human cells can be contacted with a compound of formula (I) or a form thereof in vitro or in vivo (e.g., in a non-human animal or in a human body). In a specific embodiment, the human cell is from a human or in a human body. In another specific embodiment, the human cell is from a human with HD or in a human body with HD. In another specific embodiment, the human cell is from a human with HD or in a human body with HD, and HD is caused by CAG repeats in the Htt gene, resulting in loss of HTT expression and / or function. In another embodiment, the human cell is from a human with HD. In another embodiment, the human cell is in a human body with HD. In one embodiment, the compound is in the form of a compound of formula (I).
[0420] In a specific embodiment, provided herein is a method for enhancing the inhibition of mutant HTT transcribed from the Htt gene, the method comprising contacting a human cell with a compound of formula (I) or a form thereof. The human cell can be contacted with a compound of formula (I) or a form thereof in vitro or in vivo (e.g., in a non-human animal or in a human body). In a specific embodiment, the human cell is from a human or in a human body. In another specific embodiment, the human cell is from a human with HD or in a human body with HD. In another specific embodiment, the human cell is from a human with HD or in a human body with HD, and HD is caused by CAG repeats in the Htt gene, resulting in wild-type "normal" HTT expression and / or loss of function. In another embodiment, the human cell is from a human with HD. In another embodiment, the human cell is in a human body with HD. In one embodiment, the compound is in the form of a compound of formula (I).
[0421] In another aspect, provided herein is a method for modulating the inhibition of mutant HTT transcribed from the Htt gene, the method comprising administering a compound of formula (I) or a form thereof to a non-human animal model of HD. In a specific embodiment, provided herein is a method for modulating the inhibition of mutant HTT transcribed from the Htt gene, the method comprising administering a compound of formula (I) or a form thereof to a non-human animal model of HD. In a specific embodiment, the compound is in the form of a compound of formula (I).
[0422] In another aspect, provided herein is a method for reducing the amount of mutant HTT, the method comprising contacting a human cell with a compound of formula (I) or a form thereof. In a specific embodiment, provided herein is a method for reducing the amount of mutant HTT, the method comprising contacting a human cell with a compound of formula (I) that inhibits transcription of mutant HTT (huntingtin protein mRNA) from the Htt gene. In another specific embodiment, provided herein is a method for reducing the amount of HTT, the method comprising contacting a human cell with a compound of formula (I) that inhibits expression of mutant HTT transcribed from the Htt gene. Human cells can be contacted with a compound of formula (I) or a form thereof in vitro or in vivo (e.g., in a non-human animal or in a human body). In a specific embodiment, the human cell is from a human or in a human body. In another specific embodiment, the human cell is from a human with HD or in a human body with HD. In another specific embodiment, the human cell is from a human with HD or in a human body with HD, and HD is caused by CAG repeats in the Htt gene, resulting in loss of HTT expression and / or function. In another embodiment, the human cell is from a human with HD. In another embodiment, the human cell is in a human body with HD. In one embodiment, the compound is in the form of a compound of formula (I).
[0423] In certain embodiments, treatment or improvement of HD with a compound of formula (I) or a form thereof (alone or in combination with another agent) has a therapeutic effect and / or a beneficial effect. In specific embodiments, treatment of HD with a compound of formula (I) or a form thereof (alone or in combination with another agent) results in one, two or more of the following effects: (i) reducing or improving the severity of HD; (ii) delaying the onset of HD; (iii) inhibiting the progression of HD; (iv) reducing the subject's hospitalization; (v) reducing the subject's hospitalization time; (vi) increasing the subject's survival rate; (vii) improving the subject's quality of life; (viii) reducing the number of symptoms associated with HD; (ix) reducing or improving the severity of symptoms associated with HD; (x) reducing the duration of symptoms associated with HD; (xi) preventing the recurrence of symptoms associated with HD; (xii) inhibiting the development or onset of HD symptoms; and / or (xiii) inhibiting the progression of symptoms associated with HD.
[0424] Metabolites of compounds
[0425] Also included within the scope of the present invention is the use of in vivo metabolites of the compounds described herein. These products may be produced, for example, by oxidation, reduction, hydrolysis, amidation, esterification, etc. of the administered compound, primarily due to enzymatic processes. Thus, the specification includes the use of compounds produced by a method comprising contacting a compound described herein with a mammalian tissue or mammal for a period of time sufficient to produce a metabolic product thereof.
[0426] These products are generally identified by preparing radiolabeled isotopologues of the compounds described herein (e.g., 14 C or 3 H), administering a detectable dose (e.g., greater than about 0.5 mg / kg) of a radiolabeled compound to a mammal (e.g., rat, mouse, guinea pig, dog, monkey, or human), allowing sufficient time for metabolism (usually about 30 seconds to about 30 hours), and determining metabolic conversion products from urine, bile, blood, or other biological samples. Conversion products are easily isolated because they are "radiolabeled" due to isotopic enrichment (others are isolated by using antibodies that can bind to epitopes that survive in metabolites). Metabolite structures are determined in a conventional manner, such as by MS or NMR analysis. In general, analysis of metabolites can be performed in the same manner as conventional drug metabolism studies well known to those skilled in the art. Conversion products (as long as they are not found in vivo) can be used for diagnostic determination of therapeutic doses of the compounds described herein, even if they do not have their own biological activity.
[0427] Pharmaceutical composition
[0428] Embodiments of the present invention include the use of a compound of Formula (I) or a form thereof in a pharmaceutical composition for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of a compound of Formula (I) or a form thereof mixed with one or more pharmaceutically acceptable excipients.
[0429] Embodiments of the invention include the use of a compound of formula (I) or a pharmaceutical composition of a form thereof in the preparation of a kit comprising a compound of formula (I) or a pharmaceutical composition of a form thereof and instructions for administering the compound to treat or ameliorate HD in a subject in need thereof.
[0430] As used herein, the term "composition" is intended to refer to a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
[0431] The pharmaceutical composition can be formulated to achieve a physiologically compatible pH ranging from about pH 3 to about pH 11. In some embodiments, the pharmaceutical composition is formulated to achieve a pH of about pH 3 to about pH 7. In other embodiments, the pharmaceutical composition is formulated to achieve a pH of about pH 5 to about pH 8.
[0432] The term "pharmaceutically acceptable excipient" refers to an excipient used to administer a medicament, such as a compound described herein. The term refers to any pharmaceutical excipient that can be administered without undue toxicity. A pharmaceutically acceptable excipient may be determined, in part, by the specific composition being administered, as well as the specific mode of administration and / or dosage form. Non-limiting examples of pharmaceutically acceptable excipients include carriers, solvents, stabilizers, adjuvants, diluents, and the like. Thus, there are a variety of suitable formulations for pharmaceutical compositions of the compounds of the invention described herein (see, e.g., Remington's Pharmaceutical Sciences).
[0433] Suitable excipients can be carrier molecules, which include large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive antibodies. Other exemplary excipients include antioxidants such as ascorbic acid; chelating agents such as EDTA; carbohydrates such as dextrins, hydroxyalkylcelluloses, hydroxyalkylmethylcelluloses (e.g., hydroxypropylmethylcellulose, also known as HPMC), stearic acid; liquids such as oils, water, saline, glycerol, and ethanol; wetting agents or emulsifiers; pH buffer substances; and the like. Liposomes are also included in the definition of pharmaceutically acceptable excipients.
[0434] The pharmaceutical compositions described herein can be formulated in any form suitable for the intended use described herein. Suitable formulations for oral administration include solids, liquid solutions, emulsions, and suspensions, while suitable inhalable formulations for pulmonary administration include liquids and powders. Alternative formulations include syrups, creams, ointments, tablets, and lyophilized solids, which can be reconstituted with a physiologically compatible solvent prior to administration.
[0435] When intended for oral use, tablets, troches, lozenges, aqueous or oily suspensions, non-aqueous solutions, dispersible powders or granules (including micronized granules or nanoparticles), emulsions, hard or soft capsules, syrups or elixirs can be prepared, for example. Compositions intended for oral use can be prepared according to any method of manufacturing pharmaceutical compositions known in the art, and such compositions can contain one or more agents (including sweeteners, flavoring agents, coloring agents and preservatives) to provide a palatable preparation.
[0436] Pharmaceutically acceptable excipients suitable for use in conjunction with tablets include, for example, inert diluents such as cellulose, calcium carbonate or sodium carbonate, lactose, calcium phosphate or sodium phosphate; disintegrants such as cross-linked sodium carboxymethylcellulose, cross-linked polyvinylpyrrolidone, corn starch, or alginic acid; binders such as polyvinylpyrrolidone, starch, gelatin, or gum arabic; and lubricants such as magnesium stearate, stearic acid, or talc. Tablets can be uncoated or can be coated by known techniques (including microencapsulation to delay disintegration and absorption in the gastrointestinal tract) to provide a longer sustained effect. For example, a time-delay material (such as glyceryl monostearate or glyceryl distearate) can be used alone or with a wax.
[0437] Formulations for oral use may also be presented as hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent (e.g., cellulose, lactose, calcium phosphate or kaolin), or as soft gelatin capsules in which the active ingredient is mixed with a non-aqueous medium or an oily medium (e.g., glycerol, propylene glycol, polyethylene glycol, peanut oil, liquid paraffin or olive oil).
[0438] In other embodiments, the pharmaceutical compositions described herein can be formulated as suspensions comprising a compound of formula (I) or a form thereof mixed with one or more pharmaceutically acceptable excipients suitable for making suspensions. In other embodiments, the pharmaceutical compositions described herein can be formulated as dispersible powders and granules suitable for preparing suspensions by adding one or more excipients.
[0439] Excipients suitable for use in connection with suspensions include suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, tragacanth gum, gum arabic; dispersants or wetting agents, such as naturally occurring phospholipids (e.g., lecithin), condensation products of alkylene oxides and fatty acids (e.g., polyoxyethylene stearate), condensation products of ethylene oxides and long-chain fatty alcohols (e.g., heptadecanyl ethanol), condensation products of ethylene oxides and partial esters and hexitol anhydrides derived from fatty acids (e.g., polyoxyethylene sorbitan monooleate); and thickeners, such as carbomer, beeswax, hard paraffin or cetyl alcohol. The suspension may also contain one or more preservatives, such as acetic acid, methyl paraben and / or n-propyl paraben; one or more coloring agents; one or more flavoring agents; and one or more sweeteners, such as sucrose or saccharin.
[0440] The pharmaceutical compositions described herein can also be in the form of an oil-in-water emulsion. The oil phase can be a vegetable oil, such as olive oil or peanut oil, a mineral oil, such as liquid paraffin, or a mixture of these. Suitable emulsifiers include naturally occurring gums, such as gum arabic and tragacanth; naturally occurring phospholipids, such as soy lecithin, or partial esters derived from fatty acids; hexitol anhydrides such as hexitol monooleate; condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion can also contain sweeteners and flavorings. Syrups and elixirs can be formulated with sweeteners (e.g., glycerol, sorbitol, or sucrose). Such preparations can also contain a demulcent, a preservative, a flavoring, or a coloring agent.
[0441] In addition, the pharmaceutical compositions described herein can be in the form of sterile injectable preparations, such as sterile injectable aqueous emulsions or oily suspensions. Such emulsions or suspensions can be prepared according to known techniques using those suitable dispersants or wetting agents and suspending agents mentioned above. Sterile injectable preparations can also be sterile injectable solutions or suspensions in nontoxic parenteral acceptable diluents or solvents, such as solutions in 1,2-propylene glycol. Sterile injectable preparations can also be prepared as lyophilized powders. Acceptable carriers and solvents that can be used include water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils can be used as solvents or suspension media. For this purpose, any mild fixed oil can be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids (such as oleic acid) can also be used to prepare injections.
[0442] The compounds described herein may be substantially insoluble in water and slightly soluble in most pharmaceutically acceptable protic solvents and vegetable oils, but are generally soluble in medium chain fatty acids (e.g., caprylic and capric acid) or triglycerides and propylene glycol esters of medium chain fatty acids. Thus, contemplated in the present invention are compounds modified by substitution or addition of chemical or biochemical moieties that render them more suitable for delivery (e.g., increasing solubility, biological activity, palatability, reducing adverse reactions, etc.), such as by esterification, glycosylation, pegylation, etc.
[0443] In some embodiments, the compounds described herein are formulated for oral administration in lipid-based compositions suitable for low solubility compounds. Lipid-based formulations can generally enhance the oral bioavailability of these compounds. Thus, the pharmaceutical compositions described herein can include an effective amount of a compound of formula (I) or a form thereof and at least one pharmaceutically acceptable excipient selected from medium-chain fatty acids or propylene glycol esters thereof (e.g., propylene glycol esters of edible fatty acids (e.g., caprylic fatty acids and capric fatty acids)) and a pharmaceutically acceptable surfactant (e.g., polysorbate 20 or polysorbate 80 (also known as polysorbate 80, respectively)). 20 or 80) or polyoxyethylene 40 hydrogenated castor oil).
[0444] In other embodiments, the bioavailability of low solubility compounds can be enhanced using particle size optimization techniques, which include preparing nanoparticles or nanosuspensions using techniques known to those skilled in the art. The compound forms present in such formulations include amorphous forms, partially amorphous forms, partially crystalline forms, or crystalline forms.
[0445] In alternative embodiments, the pharmaceutical composition may further include one or more water-soluble enhancers, such as cyclodextrins. Non-limiting examples of cyclodextrins include hydroxypropyl, hydroxyethyl, glucosyl, maltosyl and maltotriosyl derivatives of α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin, and hydroxypropyl-β-cyclodextrin (HPBC). In some embodiments, the pharmaceutical composition is also included in the range of about 0.1% to about 20%, about 1% to about 15%, or about 2.5% to about 10% HPBC. The amount of solubility enhancer used can depend on the amount of compound in the composition.
[0446] Preparation of compounds
[0447] The compounds provided herein can be prepared by those skilled in the art, for example, by the synthetic methods proposed in International Application Publication No. WO2014 / 028459A1 published on February 20, 2014, International Application Publication No. WO2014 / 116845A1 published on July 31, 2014, and International Application Publication No. WO2015 / 017589A1 published on February 5, 2014, each of which is incorporated herein by reference.
[0448] General approach
[0449] The following reaction schemes illustrate methods for preparing the compounds described herein. It should be understood that those skilled in the art will be able to prepare these compounds by analogous methods or by methods known to those skilled in the art.
[0450] Typically, starting components and reagents can be commercially available from various sources (e.g., commercial suppliers), synthesized according to methods known to those skilled in the art, or prepared as described herein. It should be understood that in the following description, combinations of substituents and / or variants of the described formulas are permitted only if the result of the combination produces a stable compound.
[0451] Generally, the compounds of formula (I) described herein can be synthesized according to the general scheme 1 below.
[0452] Solution 1
[0453]
[0454] General process of solution 1
[0455] The starting materials for the above reaction schemes are commercially available or can be prepared according to methods known to those skilled in the art or by methods disclosed herein. Generally, the compounds described herein are prepared in the above reaction scheme 1 as follows: using a replacement or metal-mediated cross-coupling reaction (e.g., a Buchwald reaction), a halogenated compound Ia (wherein Hal is a halogen selected from bromine or chlorine) is reacted with a compound 1b (wherein H is an active hydrogen atom in an amine or alcohol X functional group, wherein X and B of the compound of formula (I) are as described herein) to provide an intermediate compound 1c. Compound 1c is continued and reacted with a boronic acid or boronate ester compound 1d (wherein B represents a boron atom, R represents an acid or ester functional group or forms a ring system (when together with boron), and A of the compound of formula (I) is as described herein) using a transition metal-mediated cross-coupling reaction (e.g., a Suzuki reaction) to provide a compound of formula (I).
[0456] In a complementary manner, the compounds of formula (I) can also be synthesized in the reverse order, wherein the boronate compound 1d is first reacted with the compound 1a, and then the intermediate is reacted with the amine compound 1b. Other variations (representing different combinations of one or both of the boronate compound 1d and the amine compound 1b used to replace the compound 1a) are intended to be included within the scope of the synthetic methods described herein. Specific embodiments
[0458] To help understand the present invention, the following specific examples are included. Of course, experiments related to the present invention should not be interpreted as specifically limiting the present invention, and variations known now or developed later (which are within the scope of cognition of those skilled in the art) are considered to fall within the scope of the invention as described herein and hereinafter claimed.
[0459] Except in the working examples, unless otherwise stated, all the numbers used in the specification and claims to represent the number of materials, the number of reagents, reaction conditions, experimental data, etc. should be understood to be modified by the term "about". Therefore, all these digital representatives can vary according to the desired properties attempted to be obtained by the reaction or as a result of variable experimental conditions. Therefore, within the expected range of experimental reproducibility, in the context of the obtained data, the term "about" refers to the range of data provided that can vary according to the standard deviation from the mean value. Similarly, for the experimental results provided, the obtained data can be rounded up or down to present the data consistently without losing significant figures. At least, and not an attempt to limit the application of the doctrine of equivalents within the scope of the claims, each numerical parameter should be interpreted according to the number of significant figures and ordinary rounding techniques.
[0460] While the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the working examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
[0461] The column chromatography system used for product purification was ISCO CombiFlash TM Brand chromatography system (manufactured by Teledyne Isco).
[0462] Synthesis Example
[0463] More details of the present invention are provided with reference to the following non-limiting examples, which are provided to more fully illustrate the present invention, but should not be construed as limiting its scope. The examples illustrate the preparation of certain compounds described herein, as well as the testing of these compounds in vitro and / or in vivo. It will be appreciated by those skilled in the art that the techniques described in these examples represent the techniques described by the inventors that work well in the practice of the present invention, and therefore constitute the preferred mode of its practice. However, according to this disclosure, it will be appreciated by those skilled in the art that many changes may be made to the disclosed specific methods without departing from the spirit and scope of the present invention and still obtaining the same or similar results.
[0464] As used above, and throughout the specification, unless otherwise indicated, the following abbreviations shall be understood to have the following meanings:
[0465]
[0466]
[0467] Example 1 (Compound 411)
[0468] 2-{6-[8-Azabicyclo[3.2.1]oct-3-yl(methyl)amino]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol hydrochloride
[0469] Step 1: 3,6-Dibromopyridazine (133.7 mg, 0.56 mmol), (1R,5S)-3-(methylamino)-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (85 mg, 0.28 mmol) and DIPEA (0.15 mL, 0.84 mmol) were mixed in 1 mL ACN and heated to 100°C for 1 hour until LC-MS showed complete consumption of the starting material. The reaction mixture was concentrated and purified by column chromatography: gradient elution with CH2Cl2 / MeOH (0% to 30% MeOH), column: silica 4g to give (1S,5R)-3-[(6-bromopyridazin-3-yl)-methyl-amino]-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (55 mg, yield 49.25%).
[0470] Step 2:3-[(6-bromopyridazin-3-yl)-methyl-amino]-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (55 mg, 0.14 mmol), 4-[3-(methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1-tetrahydropyran-2-yl-pyrazole (68.82 mg, 0.17 mmol), Pd(dppf)Cl2 (10.34 mg, 0.01 mmol), K2CO3 (57.98 mg, 0.42 mmol) were mixed in a Schlenk tube. The reaction was degassed with N2 for 15 minutes, dioxane (2 mL) and water (0.5 mL) were added, and the reaction was heated to 90°C for 16 hours. The reaction was cooled to room temperature and partitioned between EtOAc and water. The organic layer was dried over Na2SO4, concentrated under vacuum and purified by column chromatography: gradient elution with CH2Cl2 / EtOAc (0% to 80%), column: silica 4g to give a tan solid (1S,5R)-3-[[6-[2-(methoxymethoxy)-4-(1-tetrahydropyran-2-ylpyrazol-4-yl)phenyl]pyridazin-3-yl]-methyl-amino]-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (52 mg, 62%).
[0471] Step 3: To a mixture of (1S,5R)-3-[[6-[2-(methoxymethoxy)-4-(1-tetrahydropyran-2-ylpyrazol-4-yl)phenyl]pyridazine-3-yl]-methyl-amino]-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (52 mg, 0.086 mmol) in 1 mL of CH2Cl2 and 0.5 mL of MeOH was added HCl (4 mol / L) in 1,4-dioxane (0.06 mL). The reactants were stirred overnight. The precipitate was filtered and then dried in vacuo to give a yellow solid 2-[6-[8-azabicyclo[3.2.1]oct-3-yl(methyl)amino]pyridazine-3-yl]-5-(1H-pyrazol-4)yl)phenol hydrochloride (15 mg, 42.25% yield).
[0472] LC-MS: 377[M+H] + . 1H NMR(500MHz,DMSO-d6)δ:9.37-9.51(m,IH),8.87-8.96(m,IH),8.31(d,J=9.8Hz,IH),8.12(s,2H),7.74(d,J=8.2Hz,2H),7.19-7 .27(m,2H),4.80-4.92(m,IH),4.08-4.14(m,3H),3.07(s,3H),2.30(td,J=12.6,2.8Hz,2H),1.99-2.15(m,4H),1.74-1.87(m,2H)
[0473] Using the scheme described in Example 1 above, additional compounds described herein can be prepared by substituting appropriate starting reagents and reaction conditions to provide, for example, a compound selected from the group consisting of:
[0474]
[0475] Example 2 (Compound 416)
[0476] 5-(5-methyl-1H-pyrazol-4-yl)-2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl)phenol
[0477] Step 1: 3-Methoxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)phenyl trifluoromethanesulfonate (80 mg, 0.16 mmol), (3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylic acid tert-butyl ester (59 mg, 0.19 mmol), Pd(dppf)Cl2 (7 mg, 0.01 mmol), and K2CO3 (66 mg, 0.48 mmol) were mixed in a Schlenk tube. The reactants were degassed with N2 for 15 minutes and dioxane was added. alkane (2mL) and water (0.5mL), the reaction was heated to 90 ° C for 16 hours. The reactant was cooled to room temperature and layered between EtOAc and water. The organic layer was dried over Na2SO4, concentrated under vacuum, and then purified by column chromatography: gradient elution with CH2Cl2 / MeOH (0% to 30% MeOH), column: silica 4g, to give a light brown solid 4-(3-methoxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazine-3-yl)phenyl)-3-methyl-1H-pyrazole-1-carboxylic acid tert-butyl ester (46mg, 54%).
[0478] Step 2:A solution of tert-butyl 4-(3-methoxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)phenyl)-3-methyl-1H-pyrazole-1-carboxylate (46 mg, 0.09 mmol) in 2 mL of anhydrous CH2Cl2 was cooled in an ice-water bath. 1.0 M boron tribromide (0.45 mL, 0.45 mmol) in CH2Cl2 was added and the reaction mixture was stirred at room temperature for 16 hours. The reaction was quenched with 2 mL of MeOH, stirred for 30 min, then concentrated and purified by column chromatography: gradient elution with CH2Cl2 / MeOH (2.5% NH4OH) (0% to 30% MeOH / NH4OH), column: silica 4 g to give 2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(3-methyl-1H-pyrazol-4-yl)tert-butylphenol as a yellow solid (20 mg, 55%).
[0479] LC-MS: 421[M+H] + . 1 H NMR(500MHz,DMSO-d6)δ:13.74(s,1H),12.63-12.71(m,1H),8.20(d,J=9.5Hz,1H),8.03-8.04(m,1H),7.86(d,J=8.0Hz,1H),7.73-7.75(m,1H),7. 36(d,J=9.5Hz,1H),7.03-7.06(m,2H),4.90-5.05(m,1H),2.92(s,3H),2. 43(s,3H),1.43-1.54(m,2H),1.15-1.43(m,2H),1.14(s,6H),1.09(s,6H)
[0480] Using the scheme described in Example 2 above, additional compounds described herein can be prepared by substituting appropriate starting reagents and reaction conditions to provide, for example, a compound selected from the group consisting of:
[0481]
[0482] Example 3 (Compound 419)
[0483] 2-{6-[Methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl}-5-(4-nitro-1H-pyrazol-1-yl)phenol dihydrochloride
[0484] Step 1:3-Methoxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)phenyl trifluoromethanesulfonate (335 mg, 0.67 mmol), 4-nitro-1H-pyrazole (340 mg, 4.5 mmol), Pd2(dba)3 (67 mg, 0.07 mmol), Me4tBu-XPhos (35 mg, 0.07 mmol), K3PO4 (368 mg, 1.73 mmol) were mixed in a Schlenk tube. The reactants were degassed with N2 for 15 minutes, dioxane (8 mL) was added, and the reactants were heated to 90°C for 16 hours. The reaction was cooled to room temperature, filtered through celite, concentrated and purified by column chromatography: gradient elution with CH2Cl2 / MeOH (0% to 30% MeOH), column: silica 12g to give 6-(2-methoxy-4-(4-nitro-1H-pyrazol-1-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine (202 mg, 65%).
[0485] LC-MS: 466[M+H] + . 1 H NMR (500 MHz, DMSO-d6) δ: 9.81-9.85 (m, IH), 8.61 (d, J = 0.6 Hz, IH), 7.91 (d, J = 8.5 Hz, IH), 7.81 (d, J = 9.8 Hz, IH), 7.73 (d, J = 1.9 Hz, IH), 7.68 (dd, J = 8.2, 2.2 Hz, IH), 7.10-7.21 (m, IH), 5.08-5.26 (m, IH), 3.96 (s, 3H), 2.95 (s, 3H), 1.59-1.75 (m, 4H), 1.40 (s, 6H), 1.33, (s, 6H), (1 H corresponding to OH or NH was not observed)
[0486] Step 2:6-(2-methoxy-4-(4-nitro-1H-pyrazol-1-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazine-3-amine (150 mg, 0.32 mmol), thiophenol (33 μL, 0.32 mmol) and KCO (44 mg, 0.32 mmol) were mixed in a microwave tube. The reactants were degassed with N for 15 minutes and anhydrous NMP (1.5 mL) was added. The reactants were heated at 190 ° C for 20 minutes in a Biotage microwave, then diluted with 10 mL EtOAc and washed with water and brine. The product was dried over Na2SO4, concentrated under vacuum and then purified by column chromatography: gradient elution with CH2Cl2 / MeOH (0% to 30% MeOH), column: silica 4g to give 2-(6-(methyl)(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(4-nitro-1H-pyrazol-1-yl)phenol (60 mg, 42%) as a brown solid.
[0487] LC-MS: 452[M+H] + . 1 H NMR (500 MHz, DMSO-d6) δ: 9.77 (s, 1H), 8.68 (d, J = 9.8 Hz, 1H), 8.62 (s, 1H), 8.27 (d, J = 8.8 Hz, 1H), 7.87-7.94 (m, 1H), 7.66 (dd, J = 8.5, 2.6 Hz, 1H), 7.64 (d, J = 2.6 Hz, 1H), 5.03-5.22 (m, 1H), 3.01 (s, 3H), 1.84-1.94 (m, 2H), 1.70-1.77 (m, 2H), 1.53 (s, 6H), 1.43 (s, 6H), (two hydrogens corresponding to OH and NH were not observed)
[0488] Using the scheme described in Example 3 above, additional compounds described herein can be prepared by substituting appropriate starting reagents and reaction conditions to provide, for example, a compound selected from the group consisting of:
[0489]
[0490] Example 4 (Compound 424)
[0491] 5-(1H-pyrazol-4-yl)-2-[6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]phenol trihydrochloride
[0492] Step 1:3-Bromo-6-(2-methoxy-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)phenyl)pyridazine (100 mg, 0.24 mmol), (1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridin-4-yl)boronic acid (66 mg, 0.29 mmol), PddppfCl2 (8 mg, 0.012 mmol), K2CO3 (99 mg, 0.72 mmol) were mixed in a Schlenk tube. The reaction was degassed with N2 for 15 minutes, dioxane (2 mL) and water (0.5 mL) were added, and the reaction was heated to 90°C for 16 hours. The reaction was cooled to room temperature and partitioned between EtOAc and water. The organic layer was dried over Na2SO4 and then concentrated under vacuum and purified by column chromatography: gradient elution with CH2Cl2 / MeOH (0% to 20% MeOH), column: silica 4g to give 5-(1H-pyrazol-4-yl)-2-(6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)phenol as an off-white solid (102 mg, 82%).
[0493] Step 2: 5-(1H-pyrazol-4-yl)-2-(6-(1,2,3,6-tetrahydropyridine-4-yl)pyridazine-3-yl)phenol (102mg, 0.196mmol) in 2mL anhydrous CH2Cl2 solution was cooled in an ice-water bath. 1.0M bromotribromide CH2Cl2 solution (0.98mL, 0.98mmol) was added and the reaction mixture was stirred at room temperature for 16 hours. The reaction was quenched with 2mL MeOH, stirred for 30 minutes, then concentrated and purified using preparative HPLC to give an off-white solid 5-(1H-pyrazol-4-yl)-2-(6-(1,2,3,6-)tetrahydropyridine-4-yl)pyridazine-3-yl)phenol (41mg, 66%).
[0494] LC-MS: 320[M+H] + . 1 H NMR (500 MHz, DMSO-d6) δ: 9.19 (br S, 2H), 8.54 (d, J = 9.6 Hz, 1H), 8.22, (d, J = 9.6 Hz, 1H), 8.18 (s, 1H), 8.05 (d, J = 8.8 Hz, 1H), 7.25-7.29 (m, 2H), 6.92 (s, 1H), 3.85-3.92 (m, 2H), 3.38-3.41 (m, 2H), 2.88-2.98 (m, 2H), (1 hydrogen corresponding to OH or NH was not observed)
[0495] Using the scheme described in Example 4 above, additional compounds described herein can be prepared by substituting appropriate starting reagents and reaction conditions to provide, for example, a compound selected from the group consisting of:
[0496]
[0497]
[0498] Example 5 (Compound 427)
[0499] 2-[6-(Piperidin-4-ylamino)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol tetrahydrochloride
[0500] Step 1: 3,6-Dibromopyridazine (500 mg, 2.1 mmol), 4-(3-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (970 mg, 2.52 mmol), Pd(dppf)Cl2 (77 mg, 0.11 mmol), K2CO3 (870 mg, 6.3 mmol) were mixed in a Schlenk tube. The reaction was degassed with N2 for 15 minutes, dioxane (8 mL) and water (1 mL) were added, and the reaction was heated to 90°C for 16 hours. The reaction was cooled to room temperature and partitioned between EtOAc and water. The organic layer was dried over Na2SO4, concentrated under vacuum and purified by column chromatography: gradient elution with hexanes / EtOAc (0% to 40% EtOAc), column: silica 4g to give 3-bromo-6-(2-methoxy-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)phenyl)pyridazine (690 mg, 79%) as an off-white fluffy solid.
[0501] Step 2:3-Bromo-6-(2-methoxy-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)phenyl)pyridazine (50 mg, 0.12 mmol), tert-butyl 4-aminopiperidine-1-carboxylate (36 mg, 0.18 mmol), potassium tert-butoxide (41 mg, 0.36 mmol), tBuXPhos-Pd-G3 (10 mg, 0.012 mmol) were mixed in a Schlenk tube. The reactants were degassed with Ar, then anhydrous THF (2 mL) was added and the reactants were heated to 80° C. for 12 hours. The reactants were cooled to room temperature and then layered between EtOAc and water. The organic layer was dried over Na2SO4, concentrated under vacuum and purified by column chromatography: gradient elution with CH2Cl2 / MeOH (0% to 15% MeOH), column: silica 4g to give tert-butyl 4-((6-(2-methoxy-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)phenyl)pyridazin-3-yl)amino)piperidine-1-carboxylate (45 mg, 70%) as a tan solid.
[0502] Step 3: A solution of 4-((6-(2-methoxy-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)phenyl)pyridazine-3-yl)amino)piperidine-1-carboxylate (45 mg, 0.084 mmol) in 2 mL of anhydrous CH2Cl2 was cooled in an ice-water bath. A 1.0 M solution of boron tribromide in CH2Cl2 (0.42 mL, 0.42 mmol) was added and the reaction mixture was stirred at room temperature for 16 hours. The reaction was quenched with 2 mL of MeOH, stirred for 30 minutes, then concentrated and purified using preparative HPLC to give 2-(6-(piperidin-4-ylamino)pyridazine-3-yl)-5-(1H-pyrazol-4-yl)phenol (21 mg, 73%) as a pale yellow solid.
[0503] LC-MS: 377[M+H] + . 1 H NMR(500MHz,DMSO-d6)δ:8.95(s,2H),8.25(d,J=9.6Hz,1H),8.09(s,2H),7.69(d,J=8.8Hz,1H),7.49-7.41(m,1H), 7.21-7.24(m,2H),4.11-4.15(m,1H),3.34-3.39(m,4H),3.01-3.08(m,2H),2.11-2.17(m,2H),1.79(q,J=9.2Hz,2H)
[0504] Using the scheme described in Example 5 above, additional compounds described herein can be prepared by substituting appropriate starting reagents and reaction conditions to provide, for example, a compound selected from the group consisting of:
[0505]
[0506]
[0507] Example 6 (Compound 430)
[0508] 6-[2,3-Difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine hydrochloride
[0509] Step 1: To a RBF equipped with a N2 inlet was added: 6-bromo-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)pyridazin-3-amine (90 mg, 0.28 mmol), 4-[2,3-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1-tetrahydropyran-2-yl-pyrazole (128.8 mg, 0.33 mmol), Pd(PPh3)4 (31.8 mg, 0.03 mmol), Na2CO3 (87.43 mg, 0.83 mmol). The reactants were degassed with N2 for 15 minutes, then dioxane (8 mL) and water (2 mL) were added. The reaction was heated to 90°C for 16 hours, then cooled to room temperature and partitioned between EtOAc and water. The organic layer was dried over Na2SO4, concentrated on a rotary evaporator and purified by column chromatography: gradient elution with CH2Cl2 / MeOH (0% to 30%), column: silica 4g to give a gray solid 6-(2,3-difluoro-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine (88 mg, 63%).
[0510] Step 2:6-[2,3-difluoro-4-(1-tetrahydropyran-2-ylpyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidinyl)pyridazin-3-amine (88 mg, 0.17 mmol) was dissolved in MeOH (2 mL) and a 4M HCl solution in dioxane (90 μL, 0.34 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 30 minutes until LC-MS showed that the starting material was completely consumed. The reaction mixture was concentrated under reduced pressure to give 6-(2,3-difluoro-4-(1H-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidinyl)-4-yl)pyridazin-3-amine hydrochloride.
[0511] LC-MS: 427[M+H] + . 1 H NMR(500MHz,DMSO-d6)δ:9.21-9.33(m,IH),8.27-8.43(m,IH),8.20(s,2H),8.01(d,J=9.8Hz,IH),7.60-7.79(m,3H) ,5.01-5.14(m,IH),3.05(s,3H),2.10(td,J=13.2,1.6Hz,2H),1.79(dd,J=12.9,4.1Hz,2H),1.55(s,6H),1.50(s,6H)
[0512] Using the scheme described in Example 6 above, additional compounds described herein can be prepared by substituting appropriate starting reagents and reaction conditions to provide, for example, a compound selected from the group consisting of:
[0513]
[0514]
[0515]
[0516] Example 7 (Compound 434)
[0517] 6-[2-Methoxy-6-(1H-pyrazol-4-yl)pyridin-3-yl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine hydrochloride
[0518] 6-(2-methoxy-6-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)pyridin-3-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine (6 mg) was dissolved in 1 mL 4N HCl / dioxane and the resulting mixture was stirred at room temperature for 20 minutes. The mixture was evaporated and triturated with ether to give 6-(2-methoxy-6-(1H-pyrazol-4-yl)pyridin-3-yl)-N-methyl-N-(2,2,6,6-)tetramethylpiperidin-4-yl)pyridazin-3-amine (4 mg, 75%).
[0519] LC-MS: 422[M+H] + . 1 H NMR(500MHz, methanol-d4)δ:8.42-8.47(m,1H),8.33-8.42(m,2H),8.09-8.17(m,1H),7.99-8.08(m,1H),7 .50-7.56(m,1H),5.0(m,1H),4.16(s,3H),3.20(s,3H),1.94-2.15(m,4H),1.65(s,6H),1.57(s,6H)
[0520] Example 8 (Compound 460)
[0521] 3-{6-[Methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl}-6-(1H-pyrazol-4-yl)pyridin-2-ol hydrochloride
[0522] Step 1: 6-Chloro-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine (280 mg, 1.0 mmol) was dissolved in a mixture of 10 mL of dioxane and water (4:1). To this solution was added sodium carbonate (190 mg, 3 eq.), (6-chloro-2-methoxypyridin-3-yl)boronic acid (190 mg, 1 eq.) and Pd(Ph3P)4 (70 mg, 0.1 eq.). The reaction mixture was stirred at 90°C for 16 hours, then applied to a column and purified using DCM / MeOH to give (133 mg, 55%) 6-(6-chloro-2-methoxypyridin-3-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine.
[0523] LC-MS: 390[M+H] + . 1H NMR(500MHz,DMSO-d6)δ:8.25(d,J=7.88Hz,1H),7.83(d,J=9.77Hz,1H),7.24(d,J=7.88Hz,1H),7.11(d,J=9 .77Hz,1H),5.00-5.24(m,1H),3.93(s,3H),2.87-2.96(m,3H),1.40-1.57(m,4H),1.21-1.29(m,7H),1.10(br s,6H)
[0524] Step 2: 6-(6-Chloro-2-methoxypyridin-3-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine (90 mg) was dissolved in a mixture of dioxane and water (4:1, 5 mL). To this solution were added sodium carbonate (100 mg, 3 eq.), 1-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (70 mg, 1.1 eq.) and Pd(Ph3P)4 (27 mg, 0.1 eq.). The reaction mixture was stirred at 90 °C for 16 h and then purified by column chromatography using DCM / MeOH to give 80 mg (68%) of 6-(2-methoxy-6-(1-(tetrahydro-2H-pyran)-2-yl)-1H-pyrazol-4-yl)pyridin-3-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine.
[0525] Step 3: 6-(2-Methoxy-6-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)pyridin-3-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine (45 mg) was dissolved in 4 mL of 4N HCl / dioxane and the resulting mixture was heated at 60°F for 2 hours. The resulting mixture was evaporated and triturated with ether to give 3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-6-(1H-pyrazol-4-yl)pyridin-2-ol (24 mg, 61%).
[0526] LC-MS: 408[M+H] + ; 1H NMR(500MHz, methanol-d4)δ:8.62-8.69(m,1H),8.55-8.61(m,1H),8.39(s,2H),7.95-8.06(m,1H) ),7.04-7.14(m,1H),5.02-5.24(m,1H),3.18(s,3H),2.03(s,4H),1.67(s,6H),1.57(s,6H)
[0527] Using the scheme described above in Example 8, additional compounds described herein can be prepared by substituting appropriate starting reagents and reaction conditions to provide, for example, a compound selected from the group consisting of:
[0528]
[0529] Biological Examples
[0530] The following in vitro biological examples demonstrate the effectiveness of the compounds of the present invention for treating Huntington's disease.
[0531] In order to describe in more detail and help understand the present invention, the following non-limiting biological examples are provided to more fully illustrate the scope of the present invention, but should not be interpreted as specifically limiting its scope. It is believed that these changes of the present invention known now or developed later (determined within the cognitive scope of those skilled in the art) fall within the scope of the present invention and are protected as hereinafter claimed.
[0532] Example 1
[0533] Development and Validation of the Meso Scale Discovery (MSD) Assay to Quantify Mutant Huntingtin and Total Huntingtin (HTT) - Optimal Paired Assay for Endogenous HTT Detection
[0534] In order to identify orally bioavailable small molecules for HTT reduction, a high-throughput ELISA method is needed to detect and measure total HTT (wild type and mutant) (tHTT) and mutant HTT (mHTT) in cells and tissues from HD patients and animal models. The methods described herein allow for relative high-throughput protein measurement of tHTT and mHTT levels in cells and tissues from HD patients and in HD animal models. The ELISA method described herein enables the screening of molecules for their ability to reduce HTT levels and the identification and optimization of small molecules for the treatment of HD.
[0535] To identify antibody combinations that detect HTT (wild-type and mutant forms) in a sensitive, high-throughput format, a variety of commercially available antibodies were screened for capture / detection combinations (Table 1).
[0536] Optimal paired assay for comparison of antibodies for detecting total and mutant HTT in cells
[0537] 1. Grow cells in a cell culture compatible 96-well plate.
[0538] 2. Remove the medium and add 50 μl to 100 μl of lysis buffer (composition described below) per well to the cells to provide a "cell lysate." Place the plate on a shaker at 4°C for 30 minutes and then store at -20°C.
[0539] 3. Prepare capture antibody dilution as described in the plate layout by diluting the capture antibody for the standard plate in PBS and then add 30 μl of capture antibody dilution per well. Seal the plate and incubate overnight at 4°C.
[0540] 4. Wash the plate 3 times with 200 μl wash buffer. Add blocking buffer (150 μl per well), then seal the plate and incubate on a plate shaker at room temperature (RT) for 3 to 4 hours.
[0541] 5. Pour off the blocking buffer and wash the plate 3 times with 200 μl of wash buffer. Then add the cell lysate (25 μL per well). Seal the plate and incubate overnight at 4°C.
[0542] 6. Prepare the primary detection antibody dilution by diluting the paired primary detection antibody in the assay antibody dilution. Wash the plate 3 times with 200 μl of wash buffer and then add 25 μl of the primary detection antibody dilution per well. Seal the plate and incubate on a plate shaker at room temperature for 1 hour.
[0543] 7. Prepare the secondary detection antibody dilution by diluting the paired secondary detection antibody in the assay antibody dilution. Wash the plate 3 times with 200 μL of wash buffer and then add 25 μL of the secondary detection antibody dilution per well. Seal the plate and incubate on a plate shaker at room temperature for 1 hour.
[0544] 8. Dilute the read buffer 4-fold. Wash the plate 3 times with 200 μl of wash buffer and then add 150 μl of read buffer to each well. Read the plate immediately afterwards.
[0545] Various commercially available antibodies screened in the optimal pair analysis, providing different capture / detection combinations, are shown in Table 1. The capture / detection antibody pairs evaluated are shown in Table 2. The two antibody pairs that gave the greatest transmission values (higher signal-to-noise ratio) were selected for extended polyglutamine (mHTT) and whole human HTT detection.
[0546] Table 1
[0547]
[0548] Table 2
[0549] right HTT MSD ID Signal-to-Noise Ratio Capture / Detection total MAB2166 / MAB2174 95 Capture / Detection total MAB2166 / sc-8767 6 Capture / Detection total sc-8767 / #5656 5 Capture / Detection total MAB2166 / #5656S 483 Capture / Detection Mutant MAB5374 / #5656S 8 Capture / Detection Mutant MAB1574 / #5656S 25 Capture / Detection Mutant P1874 / #5656S 20 Capture / Detection Mutant MW1 / #5656S 45
[0550] The best paired capture / detection antibody pair is characterized by those combinations that provide minimal background and maximum signal. This highly sensitive ELISA assay can be used to detect HTT in the context of drug discovery for screening reagents (small molecules and macromolecules and gene therapy), and for detecting HTT as a biomarker in clinical studies. This capture / detection antibody pair for quantifying total HTT is selected from MAB2166 / MAB2174 and MAB2166 / #5656S. This capture / detection antibody pair for quantifying mutant HTT is selected from MAB 1574 / #5656S, P1874 / #5656S and MW1 / #5656S. The antibody pair for mHTT (MW1 / #5656S) and another antibody pair for total HTT (MAB2166 / #5656S) from this analysis are further optimized and validated to provide a high-throughput assay capable of detecting HTT in patient fibroblasts and lymphocytes.
[0551] The endogenous huntingtin protein assay used in Example 2 was developed using the optimal paired antibodies identified in Table 2, which provides a highly sensitive, high-throughput detection assay for extended polyglutamine (mHTT) and total human HTT in a multicellular system. The platform used for the assay is the ELISA-based Meso Scale Discovery (MSD) electrochemiluminescent assay platform.
[0552] Example 2
[0553] Endogenous Huntington protein assay
[0554] Meso Scale Discovery (MSD) 96-well or 384-well plates were coated with MW1 (extended polyglutamine) or MAB2166 monoclonal antibodies (for capture) at a concentration of 1 μg / mL in PBS (30 μL per well) at 4° C. The plates were then washed three times with 300 μL of wash buffer (0.05% Tween-20 in PBS), blocked (100 μL of blocking buffer; 5% BSA in PBS) for 4 to 5 hours at room temperature with rotation and shaking, and then washed three times with wash buffer.
[0555] The sample (25 μL) was transferred to the MSD plate coated with the antibody and incubated overnight at 4°C. After removing the lysate, the plate was washed three times with wash buffer, and 25 μL #5656S (cell signaling; rabbit monoclonal) secondary antibody (diluted to 0.25 μg / mL in 0.05% Tween-20 blocking buffer) was added to each well and incubated at room temperature for 1 hour with shaking. After incubation with the secondary antibody, the wells were rinsed with wash buffer, after which 25 μL of goat anti-rabbit SULFO TAG secondary detection antibody (essential aspect of the MSD system) (diluted to 0.25 μg / mL in 0.05% Tween-20 blocking buffer) was added to each well and incubated at room temperature for 1 hour with shaking. After rinsing three times with wash buffer, 150 μL of read buffer T with surfactant (MSD) was added to each empty well, and the plate was imaged on an SI 6000 imager (MSD) according to the manufacturer's instructions for the 96-well plate or 384-well plate provided. The obtained IC of the tested compounds 50 The values (μM) are shown in Table 3.
[0556] As shown in Table 3, the test compounds described herein had the following IC 50 Values, single star (*) indicates IC between >3 μM and ≤9 μM 50 Values, two stars (**) indicate IC values between >1 μM and ≤3 μM 50 Three stars (***) indicate IC values between >0.5 μM and ≤1 μM 50 Four stars (****) indicate IC values between >0.1 μM and ≤0.5 μM. 50 Five stars (*****) indicate an IC value of ≤0.1 μM 50 value.
[0557] Table 3
[0558]
[0559]
[0560] Regardless of whether or not a document cited herein is specifically and individually indicated as incorporated by reference, all documents mentioned herein are incorporated by reference into this application for any and all purposes to the same extent as if each individual reference were fully set forth herein.
[0561] Having now fully described the claimed subject matter, those skilled in the art will appreciate that the same operations may be performed within a broad range of equivalents without affecting the scope of the subject matter or embodiments described herein. It is intended that the appended claims be interpreted to include all such equivalents.
Claims
1. A compound of formula (Ia11) or a salt form thereof: in, X is selected from O, NR 5a , or key; A is selected from phenyl, thienyl, indazolyl, pyridyl, pyrimidinyl, or phenoxy, wherein phenyl and phenoxy are each optionally substituted by 1, 2 or 3 substituents, each of which is selected from R 1a , wherein thienyl, indazolyl, pyridyl and pyrimidinyl are each optionally substituted by 1 or 2 substituents, each of which is selected from R 1a , R 1a Selected from halogen, hydroxyl, C 1-4 Alkyl, halo-C 1-4 Alkyl, amino, C 1-4 Alkoxy or heteroaryl, Wherein, heteroaryl is a monocyclic, bicyclic or polycyclic carbon atom ring structure group, having one or more heteroatoms selected from O, S and N, optionally substituted by one or two substituents, each of which is selected from R 3a ; When A is phenyl, R 1a is not hydroxy, chloro, or pyrazolyl; R 3a Selected from nitro, or C 1-4 alkyl; R 4a It is C 1-4 Alkyl; and R 5a It is hydrogen, C 1-4 Alkyl, or hydroxy-C 1-4 alkyl.
2. The compound or salt form thereof according to claim 1, wherein R 1a is selected from fluorine, chlorine, hydroxy, methyl, difluoromethyl, amino, methoxy or 1H-pyrazolyl or 1H-imidazol-1-yl, wherein 1H-pyrazolyl is optionally substituted by 1 or 2 substituents, each of which is selected from R 3a ; R 3a is selected from nitro or methyl; R 4a is methyl or ethyl; and R 5a is hydrogen or methyl.
3. The compound or salt form thereof according to claim 1, wherein A is selected from the group consisting of thienyl, indazolyl, pyridinyl, pyrimidinyl and phenoxy.
4. Use of the compound according to claim 1 or a salt form thereof in the manufacture of a medicament for treating or ameliorating Huntington's disease in a subject in need thereof.
5. A pharmaceutical composition comprising a compound according to claim 1 or a salt form thereof in admixture with one or more pharmaceutically acceptable excipients.
6. A compound or a salt form thereof, said compound being selected from the group consisting of: 2-{6-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol 2-[6-((1R,5S)-8-azabicyclo[3.2.1]oct-3-ylamino)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol 5-(1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl}phenol 5-(1-methyl-1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}phenol 2-[6-((1R,5S)-8-azabicyclo[3.2.1]oct-3-yloxy)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol 5-(5-methyl-1H-pyrazol-4-yl)-2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl}phenol 5-(1H-imidazol-1-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}phenol 5-(5-methyl-1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}phenol 2-{6-[Methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl}-5-(4-nitro-1H-pyrazol-1-yl)phenol 6-[2-Methoxy-4-(4-nitro-1H-pyrazol-1-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine 5-(4-amino-1H-pyrazol-1-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}phenol 2-[6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol 5-(4-nitro-1H-pyrazol-1-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}phenol 5-(1H-pyrazol-4-yl)-2-[6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]phenol 2-[6-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol 2-{6-[Methyl(piperidin-4-yl)amino]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol 2-[6-(Piperidin-4-ylamino)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol 6-[2,5-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine 2-[6-(8-Azabicyclo[3.2.1]oct-2-en-3-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol 6-[2,3-Difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine 3-[2,5-difluoro-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazine 2-[6-(Piperidin-4-yloxy)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol 2-{6-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-ylamino]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol 3-[4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazine 3-[2-Fluoro-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazine 3-[4-(1-methyl-1H-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazine 2-[6-(2,7-diazaspiro[3.5]nonan-2-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol N-Methyl-6-(2-methyl-2H-indazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine 2-Methyl-5-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}-2H-indazole N-Methyl-6-(2-methylpyrazolo[1,5-a]pyridin-3-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine 6-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}imidazo[1,2-a]pyridine 3-[2-Methoxy-4-(1H-pyrazol-1-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazine 3-[5-(1H-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazine 3-[5-(1-methyl-1H-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazine 3-[4-(1H-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazine 5-(3,5-Dimethyl-1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}phenol 6-[2-Fluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine 3-Methoxy-4-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}phenol 3-[2-Methoxy-4-(4-nitro-1H-pyrazol-1-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazine 4-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}benzene-1,3-diol 6-[2-Chloro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine 2-(1H-pyrazol-4-yl)-4-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}pyrimidin-5-amine 3-[2,6-difluoro-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazine 2-[6-(2,6-diazaspiro[3.4]octan-2-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol 3-{6-[Methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl}-6-(1H-pyrazol-4-yl)pyridin-2-ol 6-(1H-pyrazol-4-yl)-3-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}pyridin-2-ol N,2,2,6,6-Pentamethyl-N-{5-[3-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-yl}piperidin-4-amine N,2,2,6,6-Pentamethyl-N-{5-[4-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-yl}piperidin-4-amine 3-[2-(difluoromethyl)-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazine and 6-[2-(Difluoromethyl)-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine.
7. The compound or salt form thereof according to claim 6, wherein The compound or its salt form is a compound salt selected from the group consisting of: 2-{6-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol hydrochloride 2-[6-((1R,5S)-8-Azabicyclo[3.2.1]oct-3-ylamino)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol hydrochloride 5-(1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl}phenol hydrochloride 2-[6-((1R,5S)-8-Azabicyclo[3.2.1]oct-3-yloxy)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol hydrochloride 2-{6-[Methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl}-5-(4-nitro-1H-pyrazol-1-yl)phenol dihydrochloride 2-[6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol trihydrochloride 5-(1H-pyrazol-4-yl)-2-[6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]phenol trihydrochloride 2-[6-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol trihydrochloride 2-{6-[Methyl(piperidin-4-yl)amino]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol tetrahydrochloride 2-[6-(Piperidin-4-ylamino)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol tetrahydrochloride 6-[2,5-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine tetrahydrochloride 2-[6-(8-Azabicyclo[3.2.1]oct-2-en-3-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol hydrochloride 6-[2,3-Difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine hydrochloride 3-[2,5-difluoro-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazine trihydrochloride 2-{6-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-ylamino]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol hydrochloride 3-[2-Fluoro-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazine hydrochloride 2-[6-(2,7-diazaspiro[3.5]nonan-2-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol tetrahydrochloride 3-[5-(1H-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazine hydrochloride 3-[4-(1H-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazine hydrochloride 6-[2-Chloro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine trihydrochloride 3-[2,6-Difluoro-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazine trihydrochloride 3-{6-[Methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl}-6-(1H-pyrazol-4-yl)pyridin-2-ol hydrochloride N,2,2,6,6-Pentamethyl-N-{5-[3-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-yl}piperidin-4-amine hydrochloride N,2,2,6,6-Pentamethyl-N-{5-[4-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-yl}piperidin-4-amine hydrochloride 3-[2-(difluoromethyl)-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazine hydrochloride and 6-[2-(Difluoromethyl)-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine hydrochloride.
8. A pharmaceutical composition comprising a compound according to claim 6 or a salt form thereof in admixture with one or more pharmaceutically acceptable excipients.
9. A compound of formula (Ia11) or a salt form thereof: in, X is selected from O, NR 5a , or key; A is selected from phenyl, thienyl, indazolyl, pyridyl, pyrimidinyl, or phenoxy, wherein phenyl and phenoxy are each optionally substituted by 1, 2 or 3 substituents, each of which is selected from R 1a , Wherein, thienyl, indazolyl, pyridyl, pyrimidinyl are each optionally substituted by 1 or 2 substituents, each of which is selected from R 1a , R 1a Selected from halogen, hydroxyl, C 1-4 Alkyl, halo-C 1-4 Alkyl, amino, C 1-4 Alkoxy or heteroaryl, Wherein, heteroaryl is a monocyclic, bicyclic or polycyclic carbon atom ring structure group, having one or more heteroatoms selected from O, S and N, optionally substituted by one or two substituents, each of which is selected from R 3a ; When A is phenyl, R 1a Not hydroxyl; R 3a Selected from nitro, or C 1-4 alkyl; R 4a It is C 1-4 Alkyl; and R 5a It is hydrogen, C 1-4 Alkyl, or hydroxy-C 1-4 alkyl.
10. The compound or salt form thereof according to claim 9, wherein A is selected from the group consisting of thienyl, indazolyl, pyridinyl, pyrimidinyl and phenoxy.
11. The compound or salt form thereof according to claim 9, wherein R 1a is selected from fluorine, chlorine, hydroxy, methyl, difluoromethyl, amino, methoxy, 1H-pyrazolyl or 1H-imidazol-1-yl, wherein 1H-pyrazolyl is optionally substituted by 1 or 2 substituents, each of which is selected from R 3a ; R 3a is selected from nitro or methyl; R 4a is methyl or ethyl; and R 5a is hydrogen or methyl.
12. Use of the compound according to claim 9 or a salt form thereof in the manufacture of a medicament for treating or ameliorating Huntington's disease in a subject in need thereof.
13. A pharmaceutical composition comprising a compound according to claim 9 or a salt form thereof in admixture with one or more pharmaceutically acceptable excipients.
14. A compound or a salt form thereof, wherein the compound is selected from the compound of formula (Ia15) and the compound of formula (Ia18): in, X is selected from O, NR 5a , or key; B is selected from 1H-pyrazolyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, (1R,5S)-8-azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]oct-2-enyl, 2,6-diazaspiro[3.4]octyl, or 2,7-diazaspiro[3.5]nonyl, each optionally substituted with 1 or 2 substituents, each of which is selected from R 4a ; R 1a Selected from halogen, hydroxyl, C 1-4 Alkyl, halo-C 1-4 Alkyl, amino, C 1-4 Alkoxy or heteroaryl, Wherein, heteroaryl is a monocyclic, bicyclic or polycyclic carbon atom ring structure group, having one or more heteroatoms selected from O, S and N, optionally substituted by one or two substituents, each of which is selected from R 3a ; Among them, R 1a Not chlorine or pyrazolyl; R 3a Selected from nitro, or C 1-4 alkyl; R 4a It is C 1-4 Alkyl; and R 5a It is hydrogen, C 1-4 Alkyl, or hydroxy-C 1-4 alkyl.
15. The compound or salt form thereof according to claim 14, wherein R 1a is selected from fluorine, hydroxy, methyl, difluoromethyl, amino, methoxy or 1H-imidazol-1-yl, R 3a is selected from nitro or methyl; R 4a is methyl or ethyl; and R 5a is hydrogen or methyl.
16. Use of the compound according to claim 14 or a salt form thereof in the manufacture of a medicament for treating or ameliorating Huntington's disease in a subject in need thereof.
17. A pharmaceutical composition comprising a compound according to claim 14 or a salt form thereof in admixture with one or more pharmaceutically acceptable excipients.
18. A compound of formula (Ib1) or a salt form thereof: in, A is selected from the group consisting of phenyl, thienyl, indazolyl, pyridyl, pyrimidinyl and phenoxy, wherein phenyl and phenoxy are each optionally substituted by 1, 2 or 3 substituents, each of which is selected from R 1a , wherein thienyl, indazolyl, pyridyl and pyrimidinyl are each optionally substituted by 1 or 2 substituents, each of which is selected from R 1a , R 1a Selected from halogen, hydroxyl, C 1-4 Alkyl, halo-C 1-4 Alkyl, amino, C 1-4 A group consisting of an alkoxy group and a heteroaryl group, wherein heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2 or 3 heteroatom ring members selected from N, O and S, said ring system being optionally substituted with 1 or 2 substituents, each of said substituents being selected from R 3a ;as well as R 3a Selected from nitro and C 1-4 The group consisting of alkyl groups.
19. The compound or salt form thereof according to claim 18, wherein R 1a is selected from the group consisting of fluorine, chlorine, hydroxy, methyl, difluoromethyl, amino, methoxy, 1H-pyrazolyl and 1H-imidazol-1-yl, wherein 1H-pyrazolyl is optionally substituted by 1 or 2 substituents, each of which is selected from R 3a ;as well as R 3a Selected from the group consisting of nitro, methyl and amino.
20. Use of the compound or salt form thereof according to claim 18 in the manufacture of a medicament for treating or ameliorating Huntington's disease in a subject in need thereof.
21. A pharmaceutical composition comprising a compound according to claim 18 or a salt form thereof in admixture with one or more pharmaceutically acceptable excipients.
22. A compound or salt form thereof selected from the group consisting of: N,2,2,6,6-pentamethyl-N-{5-[3-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-yl}piperidin-4-amine, and N,2,2,6,6-Pentamethyl-N-{5-[4-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-yl}piperidin-4-amine.
23. The compound or salt form thereof according to claim 22, wherein The compound or its salt form is a compound salt selected from the group consisting of: N,2,2,6,6-pentamethyl-N-{5-[3-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-yl}piperidin-4-amine hydrochloride, and N,2,2,6,6-Pentamethyl-N-{5-[4-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-yl}piperidin-4-amine hydrochloride.
24. A pharmaceutical composition comprising a compound according to claim 22 or a salt form thereof in admixture with one or more pharmaceutically acceptable excipients.
